Nursing School Study Notes _ Health Concepts III Full Semester Study Guide

Heart Failure

Overview & Pathophysiology

• Heart failure is a complex clinical syndrome characterized by the inability of the heart to pump sufficient blood to meet the metabolic demands of the body's tissues.
• Heart failure typically originates with failure of the left ventricle and progressively advances to involve both ventricles.
• Cardiac output ($CO$) is determined by heart rate ($HR$) multiplied by stroke volume ($SV$):   $CO = HR \times SV$
• When cardiac output drops, compensatory mechanisms activate to restore systemic perfusion by raising heart rate, increasing stroke volume, or expanding fluid volume.

Types of Heart Failure

• Left-Sided Heart Failure (Congestive Heart Failure):
  • Systolic Heart Failure (Heart Failure with Reduced Ejection Fraction - HFrEF):
  • The left ventricle loses its ability to contract forcefully during systole, preventing adequate ejection of blood into systemic circulation.
  • Leads to an increase in both preload and afterload.
  • Ejection fraction drops below $40\%$ (normal ejection fraction range is $50\%-70\%$).
  • Results in decreased tissue perfusion and severe pulmonary congestion as blood backs up into pulmonary vessels.
  • Diastolic Heart Failure (Heart Failure with Preserved Left Ventricular Function - HFpEF):
  • The left ventricle maintains a normal ejection fraction, but experiences impaired relaxation during diastole, restricting proper filling of cardiac chambers.
  • Ventricular walls become progressively stiffened over time, leading to reduced end-diastolic volume.
  • Predominantly observed in older adults and women with underlying hypertension or coronary artery disease.
• Right-Sided Heart Failure:
  • Caused by primary left ventricular failure, right ventricular myocardial infarction, or chronic pulmonary hypertension.
  • The right ventricle is unable to empty completely, generating elevated systemic venous pressures that manifest as peripheral edema and organ congestion.
• High-Output Heart Failure:
  • Cardiac output remains normal or elevated, but metabolic demands of peripheral tissues exceed cardiac delivery capacities.
  • Caused by hypermetabolic states such as septicemia, high fever, severe anemia, and hyperthyroidism.

NYHA Functional Classifications

• Class I: Cardiac disease present, but no physical limitations or symptoms during ordinary activity.
• Class II: Mild limitations; patient experiences symptoms during ordinary physical activity.
• Class III: Marked limitations; patient experiences symptoms during minimal physical activity, but comfortable at rest.
• Class IV: Severe limitations; patient experiences symptoms at rest and is unable to carry out any physical activity without discomfort.

Compensatory Mechanisms

• Sympathetic Nervous System (SNS) Stimulation:
  • Norepinephrine and epinephrine release increases heart rate (raising $CO$), but significantly raises myocardial oxygen demand.
  • Enhances venous return, producing myocardial stretch/dilation and forceful contractions (raising stroke volume).
  • Induces arterial vasoconstriction, elevating blood pressure while simultaneously increasing afterload and myocardial work.
• Renin-Angiotensin System (RAS):
  • Diminished renal perfusion triggers renin release, initiating Angiotensin II production which causes vasoconstriction and ventricular remodeling.
  • Aldosterone secretion promotes renal sodium and water retention, expanding intravascular volume.
  • Substantially elevates preload and afterload.
• Chemical and Hormonal Responses:
  • B-type Natriuretic Peptide (BNP): Secreted by ventricular myocytes in response to prolonged stretch and fluid overload.
  • Antidiuretic Hormone (ADH): Released by the posterior pituitary gland in response to decreased cerebral perfusion; causes systemic arterial vasoconstriction and fluid retention, exacerbating heart failure symptoms.
• Myocardial Hypertrophy:
  • Structural enlargement of cardiac muscle fibers to increase contractile force; frequently leads to coronary insufficiency due to inadequate microvascular oxygen delivery to hyper-developed muscle tissues.

Etiology & Risk Factors

• Hypertension
• Coronary artery disease
• Cardiomyopathy
• Substance abuse (alcohol, illicit drugs)
• Valvular heart disease
• Congenital heart defects
• Cardiac infections or inflammatory conditions
• Cardiac dysrhythmias
• Diabetes mellitus
• Smoking and tobacco use
• Family history of cardiovascular disease
• Obesity
• Severe chronic lung disease
• Obstructive sleep apnea
• Hyperthyroidism

Clinical Manifestations

• Left-Sided Heart Failure:
  • Fatigue and generalized weakness
  • Daytime oliguria paired with nighttime nocturia
  • Angina, chest pain, and palpitations
  • Confusion, restlessness, and dizziness
  • Tachycardia, pallor, weak peripheral pulses, and cool extremities
  • Persistent cough (worse at night), dyspnea, breathlessness, orthopnea, and paroxysmal nocturnal dyspnea (PND)
  • Bilateral basilar crackles moving upward, fine profuse crackles, wheezing (narrowed bronchioles from engorged pulmonary vessels)
  • Frothy, pink-tinged sputum
  • Tachypnea and presence of $S_3$ or $S_4$ summation gallop
• Right-Sided Heart Failure:
  • Systemic venous congestion and jugular vein distention (JVD)
  • Hepatomegaly, splenomegaly, and distended abdomen (ascites)
  • Anorexia, nausea, and gastrointestinal distress
  • Dependent edema in legs, ankles, sacrum, and scrotum (in bedridden patients)
  • Swollen hands and fingers
  • Polyuria at night
  • Rapid weight gain
  • Blood pressure changes (hypertension from volume expansion or hypotension from pump failure)

Diagnostic Evaluation & Laboratory Findings

• Physical Assessment:
  • Pulsus alternans (alternating strong and weak arterial pulse peaks); require a full single-minute apical pulse assessment.
  • Frequent premature atrial contractions (PACs), premature ventricular contractions (PVCs), and atrial fibrillation.
  • Respiratory rate $> 20\,\text{breaths/min}$.
  • Measurement of abdominal girth and systematic palpation for organomegaly.
• Laboratory Tests:
  • Serum Electrolytes: Direct monitoring required due to diuretic therapy side effects.
  • Renal Function: Elevated BUN, elevated serum creatinine, and reduced creatinine clearance secondary to hypoperfusion.
  • Microalbuminuria: Serves as an early indicator of cardiac-induced renal injury.
  • B-Type Natriuretic Peptide (BNP): Confirms heart failure origin in patients presenting with acute dyspnea.
  • Arterial Blood Gases (ABGs): Hypoxemia; initial respiratory alkalosis (hyperventilation) progressing to respiratory acidosis ($\text{CO}_2$ retention) or metabolic acidosis (lactic acid accumulation from tissue hypoperfusion).
  • Thyroid Profile ($T_4$ & TSH): Indicated for patients $> 65\,\text{years}$, those with atrial fibrillation, or history of thyroid disorders.
  • Cardiac Troponins: Assesses concurrent myocardial ischemia or acute infarction.
• Diagnostic Imaging & Invasive Procedures:
  • Echocardiogram: Diagnostic test of choice; evaluates ejection fraction ($\le 40\%$ confirms heart failure), valvular integrity, chamber enlargement, and ventricular hypertrophy. Performed via Transthoracic (TTE) or Transesophageal (TEE) approaches.
  • Chest X-Ray: Identifies cardiomegaly and pulmonary vascular congestion/pleural effusion.
  • Multigated Acquisition (MUGA) Scans: Accurately calculates left ventricular ejection fraction and wall velocity.
  • Electrocardiogram (ECG): Identifies underlying hypertrophy, dysrhythmias, and ischemic changes.
  • Hemodynamic Monitoring: Central Venous Pressure (CVP) monitoring via superior vena cava into right atrium; normal range is $8-12\,mmHg$. CVP $< 8\,mmHg$ indicates hypovolemia; CVP $> 12\,mmHg$ indicates hypervolemia or right-sided heart failure.

Pharmacological Management

• Early Heart Failure Goals: Reduce preload, afterload, fluid volume, heart rate, and contractility workload.
• Late Heart Failure Goals: Enhance overall systemic perfusion by increasing contractility, heart rate, and intravascular volume support.
• Drug Classes & Specific Nursing Considerations:
  • ACE Inhibitors (e.g., lisinopril, captopril) & ARBs (e.g., losartan, valsartan):
  • Mechanism: Relaxes arterioles, suppresses renin-angiotensin-aldosterone axis, reduces afterload/preload.
  • Considerations: Monitor for first-dose hypotension, hyperkalemia, and angioedema. Discontinue ACEIs if persistent dry cough develops; substitute with ARB. Less effective as monotherapy in Black patients.
  • Diuretics:
  • Loop Diuretics (e.g., furosemide): Inhibits reabsorption of sodium, potassium, calcium, magnesium, and chloride. Rapid onset. Risk of ototoxicity and severe hypokalemia.
  • Thiazide Diuretics: Inhibits sodium, potassium, chloride, and magnesium reabsorption. Milder effect.
  • Potassium-Sparing Diuretics (e.g., spironolactone): Inhibits sodium reabsorption while retaining potassium. Risk of hyperkalemia. Assess baseline renal function.
  • Nursing: Administer early in the morning to prevent nocturia; closely track serum electrolytes and daily weights.
  • Nitrates (e.g., nitroglycerin):
  • Mechanism: Venous vasodilation; reduces preload and workload.
  • Considerations: Monitor blood pressure for hypotension; headache is an expected side effect. Tolerance develops rapidly; maintain a $12\,\text{hour}$ nitrate-free interval daily.
  • Cardiac Glycosides (e.g., digoxin):
  • Mechanism: Positive inotrope, negative chronotrope; increases contractility, reduces heart rate, slows AV node conduction.
  • Considerations: Narrow therapeutic index. Risk of toxicity increases with hypokalemia or hypomagnesemia. Signs of toxicity: nausea, vomiting, abdominal pain, extreme fatigue, confusion, bradycardia, visual disturbances (halo/blurred vision), and dysrhythmias. Antidote is Digoxin Immune Fab (DigiFab). Assess apical pulse for $1\,\text{full minute}$ prior to administration; hold if $HR < 60\,\text{bpm}$ or $HR > 100\,\text{bpm}$. Do not administer with antacids or laxatives.
  • Beta-Adrenergic Agonists (e.g., dobutamine, dopamine):
  • Mechanism: Increases cardiac contractility and stroke volume.
  • Considerations: Continuous IV infusion in critical care settings. Monitor for tachyarrhythmias, angina, and rebound hypertension.
  • Beta-Adrenergic Blockers (carvedilol [nonselective], metoprolol [selective]):
  • Mechanism: Inhibits sympathetic drive, lowering heart rate and myocardial workload.
  • Considerations: Monitor for severe bradycardia and hypotension. Assess apical pulse before administration.
  • HCN Channel Blockers (e.g., ivabradine):
  • Mechanism: Inhibits cardiac pacemaker $I_f$ current in the sinus node, lowering heart rate.
  • Considerations: Take with meals. Avoid grapefruit juice. Monitor for bradycardia, hypertension, and visual phosphenes.
  • ARNI - Angiotensin Receptor/Neprilysin Inhibitor (e.g., sacubitril/valsartan [Entresto]):
  • Mechanism: Simultaneously blocks RAAS and prevents breakdown of natriuretic peptides.
  • Considerations: Contraindicated with ACEIs, ARBs, potassium-sparing diuretics, or NSAIDs. Monitor for hyperkalemia, renal impairment, and angioedema.

Medical, Surgical, and Mechanical Interventions

• CPAP (Continuous Positive Airway Pressure): Improves ejection fraction by reducing preload, afterload, and sleep apnea-induced dysrhythmias.
• Cardiac Resynchronization Therapy (CRT): Employs a biventricular pacemaker or ICD to synchronize ventricular contractions, enhancing mean arterial pressure and cardiac output.
• Ventricular Assist Devices (VADs): Mechanical pumps implanted alongside the heart to support output. Used as a bridge to transplantation or destination therapy. Contraindicated in end-stage renal disease, severe chronic lung disease, severe clotting disorders, or active systemic infections.
• Heart Transplantation: Definitive treatment for end-stage failure; restricted by severe comorbid exclusions.

Severe Complications

• Acute Pulmonary Edema:
  • Pathophysiology: Rapid accumulation of fluid within pulmonary alveolar and interstitial spaces.
  • Signs & Symptoms: Severe dyspnea at rest, ascending crackles, tachypnea, hypoxia, acute respiratory distress, extreme anxiety, tachycardia, frothy pink sputum, disorientation, reduced urine output.
  • Interventions: Position patient in high-Fowler's with legs dangling; administer oxygen at $5-12\,L/min$ via facemask (or prep for BiPAP/CPAP/intubation if $SpO_2 < 90\%$); administer IV push furosemide, IV nitroglycerin, and IV morphine; monitor vitals every $30-60\,\text{minutes}$.
• Cardiogenic Shock:
  • Pathophysiology: Inability of the heart to maintain tissue perfusion, typically following an acute myocardial infarction affecting $\ge 40\%$ of the left ventricle.
  • Signs & Symptoms: Hypotension, tachycardia, cold/clammy skin, diminished peripheral pulses, severe oliguria, altered mental status, tachypnea, pulmonary crackles.
  • Interventions: Emergency airway management, positive inotropic infusions (dopamine, dobutamine, milrinone), vasopressors, IV diuretics, continuous hemodynamic monitoring.

Patient Education & Discharge Teaching (MAWDS)

• Medications: Take exactly as prescribed; avoid NSAIDs due to severe sodium/water retention risks.
• Activity: Maintain active lifestyle without triggering dyspnea. Perform exercise where talking during activity is comfortable. Report declining tolerance lasting $2-3\,\text{days}$.
• Weight: Weigh daily at the same time, using the same scale, after voiding and before breakfast. Report weight gain of $2\,lbs$ in $1\,\text{day}$ or $3\,lbs$ in $1\,\text{week}$.
• Diet: Limit sodium intake to $2-3\,g/day$; restrict fluid intake to $2\,L/day$. Limit dairy products and pre-packaged/canned foods.
• Symptoms: Report cold/cough lasting $3-5\,\text{days}$, excessive nocturia, dyspnea at rest, worsening angina, or peripheral swelling in extremities.

Pediatric Cardiac Defects

Normal Fetal Circulation

• Ductus Arteriosus: Vascular channel connecting the pulmonary artery directly to the descending aorta, bypassing non-functional fetal lungs.
• Foramen Ovale: Anatomic interatrial opening allowing direct blood flow from the right atrium to the left atrium.
• Ductus Venosus: Vascular channel bypassing fetal liver circulation.
• Postnatal Closure Times: Ductus venosus closes within several days after birth. Ductus arteriosus and foramen ovale functionally close within minutes to hours post-delivery.

Hemodynamic Classification & Pathophysiology

• Defects Increasing Pulmonary Blood Flow (Left-to-Right Shunts):
  • Blood flows from the high-pressure left side (oxygenated) to the low-pressure right side (deoxygenated).
  • Leads to pulmonary hyperperfusion and left-sided heart failure symptoms (dyspnea, tachypnea, fatigue, pallor).
  • Acyanotic lesions.
• Mixed / Obstructive / Decreased Pulmonary Flow Defects (Right-to-Left Shunts):
  • Blood flows from the right side (deoxygenated) directly into systemic circulation on the left side.
  • Produces systemic hypoxia, severe cyanosis, clubbing, tachypnea, and failure to thrive.
  • Cyanotic lesions.

Specific Congenital Cardiac Defects

• Ventricular Septal Defect (VSD):
  • Pathophysiology: Abnormal opening in the ventricular septum creating a left-to-right shunt.
  • Clinical Findings: Loud, harsh murmur audible at the left sternal border; systemic heart failure signs.
  • Management: Diuretics; spontaneous closure may occur. Surgical patch repair or cardiac catheterization closure.
• Atrial Septal Defect (ASD):
  • Pathophysiology: Abnormal opening in the atrial septum creating a left-to-right shunt.
  • Clinical Findings: Systolic murmur with a characteristic fixed split second heart sound ($S_2$); often asymptomatic or mild HF.
  • Management: Low-dose aspirin, diuretics; cardiac catheterization device closure or surgical patch closure.
• Patent Ductus Arteriosus (PDA):
  • Pathophysiology: Failure of the fetal ductus arteriosus to close, causing blood to flow from aorta back into pulmonary artery (left-to-right shunt).
  • Clinical Findings: Continuous machine-like systolic murmur, wide pulse pressure ($> 60\,mmHg$ difference between systolic and diastolic), bounding pulses, pulmonary rales, tachypnea.
  • Management: Indomethacin (prostaglandin inhibitor to induce closure), high-calorie density nutrition, diuretics, cardiac catheterization coil occlusion, or thoracoscopic ligation.
• Tetralogy of Fallot (TOF):
  • Pathophysiology: Four classic anomalies: (1) Pulmonary artery stenosis, (2) Ventricular septal defect, (3) Overriding aorta, (4) Right ventricular hypertrophy. Results in right-to-left shunting.
  • Clinical Findings: Cyanosis at birth that worsens over time, systolic murmur, hypercyanotic episodes ("Tet spells" triggered by crying, feeding, or agitation).
  • Management: Position child in knee-chest position during Tet spells; administer oxygen and morphine. Prostaglandin E1 (misoprostol) infusion to maintain ductal patency prior to repair. Surgical palliative shunt, followed by complete surgical repair within the first year of life.
• Coarctation of the Aorta:
  • Pathophysiology: Localized narrowing of the aortic lumen restricting systemic ventricular outflow.
  • Clinical Findings: High blood pressure and bounding pulses in the upper extremities; marked hypotension, cool skin, and weak or absent femoral/lower extremity pulses.
  • Management: Balloon angioplasty or stent insertion; long-term antihypertensive therapy if hypertension persists post-repair.

Hemophilia

Pathophysiology & Etiology

• Inherited bleeding disorders characterized by deficiencies in specific coagulation cascade clotting factors.
• Hemophilia A (Classic Hemophilia):
  • Caused by Factor VIII deficiency.
  • Accounts for $80\%$ of all hemophilia cases.
  • X-linked recessive inheritance (primarily affects males).
• Hemophilia B (Christmas Disease):
  • Caused by Factor IX deficiency.
  • X-linked recessive inheritance.
• Von Willebrand Disease (Angiohemophilia):
  • Deficiency or impairment of Von Willebrand factor (VWF).
  • Autosomal dominant or recessive inheritance; affects males and females equally.

Disease Severity Classifications

• Mild Hemophilia: Clotting factor levels are $5\%-49\%$ of normal. Bleeding occurs only after severe trauma, dental extraction, or major surgery.
• Moderate Hemophilia: Clotting factor levels are $1\%-5\%$ of normal. Excessive bleeding occurs after moderate trauma or minor injuries.
• Severe Hemophilia: Clotting factor levels are $< 1\%$ of normal. Spontaneous bleeding occurs without identifiable trauma; often identified in early infancy.

Clinical Manifestations

• Excessive, persistent bleeding from minor cuts or procedural sites
• Severe, disproportionate pain following minor trauma
• Extensive, deep cutaneous and intramuscular ecchymosis
• Hemarthrosis: Bleeding directly into joint cavities (knees, elbows, ankles), causing joint swelling, erythema, severe pain, loss of mobility, and chronic joint destruction
• Epistaxis and spontaneous bleeding from oral mucosa/gums
• Hematuria and melena or hematochezia
• Intracranial Hemorrhage: Manifests as severe headache, blurred vision, projectile vomiting, altered level of consciousness, and seizures.

Laboratory & Diagnostic Findings

• Partial Thromboplastin Time (PTT): Significantly prolonged.
• International Normalized Ratio (INR): Prolonged in specific factor severe states.
• Prothrombin Time (PT): Normal.
• Platelet Count: Normal.
• Factor Assays: Reveals low levels of Factor VIII or Factor IX.
• Von Willebrand Factor Assay: Decreased VWF antigen and activity.

Therapeutic Interventions & Patient Safety

• Factor Replacement Therapy: Intravenous administration of recombinant Factor VIII or IX concentrates. Approximately $30\%$ of severe patients develop inhibitor antibodies against factor concentrates, requiring higher dosages or bypass agents.
• Desmopressin (DDAVP): Stimulates transient release of stored endogenous Factor VIII and VWF; effective for mild Hemophilia A.
• Antifibrinolytic Therapy: Tranexamic acid or aminocaproic acid to stabilize mucosal and dental mucosal clots.
• Emicizumab: Monoclonal antibody that bridges activated Factor IX and Factor X to mimic Factor VIII function; administered subcutaneously monthly.
• Nursing Safety & Education:
  • Absolutely avoid intramuscular (IM) injections; utilize subcutaneous or oral routes.
  • Strictly avoid medications with antiplatelet or anticoagulant properties (e.g., aspirin, NSAIDs).
  • Avoid contact sports; encourage non-contact activities.
  • Apply continuous direct pressure for a minimum of $10\,\text{minutes}$ plus topical ice application to acute bleed sites.
  • Maintain meticulous oral hygiene using soft-bristled toothbrushes.

Iron Deficiency Anemia

Pathophysiology & Causes

• A microcytic, hypochromic anemia caused by inadequate total body iron required for proper hemoglobin synthesis.
• Primary Causes:
  • Inadequate Dietary Intake: Poor nutrition, chronic alcoholism, malabsorption syndromes (celiac disease, post-gastrectomy).
  • Increased Demand: Pregnancy, lactation, rapid adolescent growth spurts, chronic infection.
  • Chronic Blood Loss: Occult gastrointestinal hemorrhage, heavy menstrual bleeding (menorrhagia).

Risk Factors

• Female gender (menstruation and pregnancy)
• Older adults (inadequate nutrition, chewing/swallowing difficulties)
• Bariatric surgical procedures
• Chronic alcohol abuse
• Active GI ulceration or inflammatory bowel disease

Clinical Findings

• Generalized fatigue, pallor, cool extremities, and cold intolerance
• Exertional dyspnea, reduced exercise capacity, and dizziness
• Fissures/angular cheilitis at the corners of the mouth
• Glossitis: Smooth, painful, beefy-red tongue
• Koilonychia: Brittle, concave, spoon-shaped fingernails (chronic state)
• Tachycardia, cardiac murmurs, and orthostatic hypotension

Laboratory Diagnostic Metrics

• Hemoglobin & Hematocrit: Significantly decreased.
• Reticulocyte Count: Low (reflecting impaired bone marrow production).
• Serum Iron & Ferritin Levels: Decreased.
• Total Iron Binding Capacity (TIBC): Markedly elevated.
• Red Cell Indices: Low Mean Corpuscular Volume (MCV), low Mean Corpuscular Hemoglobin (MCH), low Mean Corpuscular Hemoglobin Concentration (MCHC).

Nursing Interventions & Pharmacotherapy

• Oral Iron Supplementation (e.g., Ferrous Sulfate):
  • Best absorbed on an empty stomach with acidic fluids (Vitamin C/ascorbic acid enhances absorption).
  • May cause severe gastrointestinal distress; taking with meals is acceptable if compliance is threatened.
  • Avoid co-administration with milk, dairy products, or calcium supplements (calcium inhibits iron absorption).
  • Warn patients that stools will turn green-black and tarry.
• Parenteral Iron (Iron Dextran / Ferumoxytol):
  • Administered IV when oral route is ineffective or poorly tolerated.
  • High risk of anaphylactic reactions; administer a $25\,mL$ test dose over $5\,\text{minutes}$ and monitor for signs of collapse prior to giving full dose.
• Dietary Interventions: Consume red meat, organ meats, egg yolks, kidney beans, leafy green vegetables, and raisins.

Sickle Cell Anemia

Genetic Pathophysiology

• An autosomal recessive hemoglobinopathy caused by a point mutation in the beta-globin gene, resulting in abnormal Hemoglobin S (HbS).
• Individuals inheriting one gene are heterozygous carriers (Sickle Cell Trait - AS) possessing $< 40\%$ HbS; individuals inheriting two genes are homozygous (Sickle Cell Disease - SS) possessing $80\%-100\%$ HbS.
• Pathodynamic Process:
  • Under conditions of low oxygen tension, dehydration, or cellular stress, HbS molecules polymerize into rigid, crystal-like rods, distorting normal pliable erythrocytes into rigid, sickle/crescent shapes.
  • Sickled red blood cells live only $10-20\,\text{days}$ (compared to normal red blood cells which live $120\,\text{days}$).
  • Sickled RBCs are sticky, fragile, and clump together, lodging in small blood vessels and causing microvascular occlusion.
  • Microvascular occlusion produces tissue ischemia, severe infarction, deep organ damage, and extreme pain (Vaso-Occlusive Crisis - VOC).
  • Re-oxygenation can temporarily restore cell shape, but repeated sickling damages cell membranes, causing permanent sickling.

Triggers for Vaso-Occlusive Events

• Systemic hypoxia or local tissue hypoxemia
• Dehydration and hyperosmolality
• Bacterial or viral infections
• Environmental exposure to cold or extreme heat
• Venous stasis and strenuous exercise
• Alcohol intake, smoking, and anesthesia
• High altitude exposure or unpressurized flight
• Emotional stress and metabolic acidosis

Systemic Manifestations

• General: Severe unrelenting pain, extreme fatigue, dizziness, low-grade fever, visual disturbances.
• Cardiovascular: Tachycardia, lower baseline blood pressure, systolic murmurs, audible $S_3$, JVD, cool extremities with delayed capillary refill, weak peripheral pulses.
• Respiratory: Shortness of breath, pulmonary hypertension, recurrent pneumonia.
• Integumentary: Pallor, jaundice (scleral icterus and oral mucosal yellowing), severe lower extremity ulcers over the malleoli due to poor cutaneous perfusion.
• Abdominal/Renal: Right upper quadrant pain from hepatic/splenic ischemia, splenomegaly, hepatomegaly, proteinuria, oliguria, and eventual renal failure.
• Musculoskeletal: Severe joint pain, osteonecrosis/avascular necrosis of bone, dactylitis (painful swelling of hands and feet in infants).
• Central Nervous System: Seizures, ischemic or hemorrhagic stroke, pronator drift, asymmetrical handgrip strength, gait disturbances.

Diagnostic & Laboratory Parameters

• Hemoglobin Electrophoresis: Definitive diagnosis; measures exact percentage of HbS.
• Hematocrit: Decreased to $20\%-30\%$ due to continuous hemolysis.
• Reticulocyte Count: Markedly elevated (compensatory marrow response).
• Serum Bilirubin: Significantly elevated due to rapid red cell destruction.
• White Blood Cell Count: Elevated due to chronic systemic inflammation.
• Imaging: X-rays, MRI, CT, and Ultrasound identify bone necrosis and organ injury.

Therapeutic Interventions & Nursing Care

• Acute Crisis Management:
  • Oxygen Therapy: Administer humidified oxygen to prevent nasal airway drying.
  • Hydration: Initiate rapid IV fluid replacement and oral fluids; maintenance rate must be at least $200\,mL/hr$.
  • Analgesia: Administer scheduled IV opioids (morphine, hydromorphone) via PCA pump. Avoid meperidine due to neurotoxicity/seizure risks.
  • Hydroxyurea Therapy: Increases fetal hemoglobin (HbF) production, inhibiting HbS polymerization and decreasing crisis frequency. Side effects include leukopenia, teratogenicity, and long-term risk of leukemia.
  • Transfusion Therapy: Packed red blood cell transfusions restore oxygen delivery; monitor for iron overload (hemosiderosis).
  • Hematopoietic Stem Cell Transplantation (HSCT): Potential cure, limited by donor availability and treatment toxicity.
• Nursing Safety Guidelines:
  • Remove restrictive clothing; keep room temperature at or above $72^\circ\text{F}$ ($22.2^\circ\text{C}$).
  • Do not elevate the head of the bed past $30\,\text{degrees}$; do not flex knees on the bed frame.
  • Do not use automatic blood pressure cuffs on affected extremities during a crisis.
• Patient Education:
  • Maintain daily fluid intake of $3-4\,L/day$.
  • Avoid alcohol, tobacco, unpressurized aviation, and high altitudes.
  • Prohibit oral contraceptives containing estrogen due to heightened thromboembolic risks.

Severe Complications

• Acute Chest Syndrome:
  • Vaso-occlusion within pulmonary microcirculation or pulmonary embolism.
  • Clinical signs: Fever, chest pain, cough, tachypnea, wheezing, leukocytosis, and new pulmonary infiltrates on chest X-ray.
  • Leading cause of mortality in adult sickle cell patients.
  • Interventions: IV antibiotics, oxygen, exchange transfusions, and pain management.
• Additional Complications: Progressive auto-splenectomy, severe sepsis, priapism, stroke, and Multiple Organ Dysfunction Syndrome (MODS).
• Life Expectancy: Average $42\,\text{years}$ for males, $48\,\text{years}$ for females.

Fluid Volume Overload

Pathophysiology & Etiology

• Hypervolemia refers to an excessive accumulation of fluid in the extracellular compartment (intravascular and interstitial space).
• Primary Causes:
  • Heart failure and chronic renal failure
  • Cirrhosis of the liver
  • Excessive IV fluid resuscitation or rapid blood administration
  • Corticosteroid administration and severe systemic stress
  • Hyperaldosteronism

Systemic Manifestations

• Cardiovascular: Tachycardia, elevated blood pressure, bounding peripheral pulses, jugular vein distention (JVD), engorged varicose veins, rapid weight gain.
• Respiratory: Tachypnea, dyspnea, shallow respirations, persistent cough, moist basilar crackles.
• Integumentary: Dependent pitting edema (legs, sacrum), pale cool skin.
• Neuromuscular: Altered level of consciousness, headache, visual disturbances, paresthesias, muscle weakness.
• Gastrointestinal: Hepatomegaly, hyperactive bowel sounds, abdominal distention.

Laboratory Findings

• Hemodilution causes decreased numerical values across multiple parameters:
  • Hemoglobin and Hematocrit: Decreased.
  • Serum Osmolality: Low.
  • Serum Sodium & Electrolytes: Decreased (dilutional hyponatremia).
  • Urine Specific Gravity and BUN: Low.

Nursing Interventions

• Monitor respiratory status every $2\,\text{hours}$ for early signs of acute pulmonary edema.
• Turn and reposition patient every $2\,\text{hours}$; utilize pressure-relieving mattresses to prevent breakdown of edematous skin.
• Obtain daily weights every morning at the same time using the same scale; report weight gains of $> 2\,lbs$ in $24\,\text{hours}$ or $> 3\,lbs$ in $7\,\text{days}$.
• Enforce strict fluid and sodium restrictions based on clinical severity.
• Administer prescribed loop or thiazide diuretics if renal function is preserved.

Cancer Overview, Staging, and Prevention

Comparative Cellular Biology

• Normal Cells:
  • Division: Slow or non-dividing.
  • Appearance: Specific differentiated features.
  • Functions: Fully specialized.
  • Adherence: Tight adherence (cadherins).
  • Migration: Non-migratory.
  • Growth: Strictly regulated via contact inhibition.
  • Chromosomes: Diploid ($46$ chromosomes).
• Benign Tumor Cells:
  • Division: Continuous or inappropriate expansion.
  • Appearance: Resembles parent cell.
  • Functions: Retains parent cell specialization.
  • Adherence: Tight adherence.
  • Migration: Non-migratory.
  • Growth: Expansion into open space; non-invasive.
  • Chromosomes: Diploid.
• Malignant Tumor Cells:
  • Division: Rapid, continuous, unlimited.
  • Appearance: Anaplastic (loss of specific appearance).
  • Functions: Loses specialized function.
  • Adherence: Loose adherence.
  • Migration: Highly migratory (invasive).
  • Growth: Loss of contact inhibition; invades surrounding tissues.
  • Chromosomes: Aneuploid (abnormal structures/numbers).

Steps of Carcinogenesis

1. Initiation: Permanent DNA mutation triggered by carcinogens, oncogenic viruses (e.g., EBV, HBV, HCV, HPV, HIV, HTLV-I/II), or genetic errors, turning off tumor-suppressor genes.
2. Promotion: Accelerated growth of the initiated cell by promoter agents (e.g., estrogen, insulin).
3. Progression: Continued change of cancer cells, acquiring an independent blood supply via Vascular Endothelial Growth Factor (VEGF) secretion.
4. Metastasis: Malignant cells break off primary tumors and establish secondary colonies via direct tissue penetration, expansion pressure, blood vessel invasion, or lymphatic spread.

TNM Staging Classification System

• Primary Tumor (T):
  • TX: Primary tumor cannot be evaluated.
  • T0: No evidence of primary tumor.
  • T1, T2, T3, T4: Increasing size and local anatomical extent of the primary tumor.
• Regional Lymph Nodes (N):
  • NX: Regional lymph nodes cannot be evaluated.
  • N0: No regional lymph node metastasis.
  • N1, N2, N3: Increasing involvement and number of regional lymph nodes.
• Distant Metastasis (M):
  • MX: Distant metastasis cannot be evaluated.
  • M0: No distant metastasis.
  • M1: Distant metastasis present.

Cancer Prevention Protocols

• Primary Prevention:
  • Avoid tobacco smoke, alcohol excess, asbestos, and hazardous industrial chemicals.
  • Apply sunscreen and avoid UV radiation exposure.
  • Consume low-fat, high-fiber diets; restrict red meats and processed fats.
  • Administer prophylactic vaccines (HPV, Hepatitis B).
• Secondary Prevention (Screening):
  • Breast Self-Exam & Mammography: Optional annual mammograms ages $35-44\,\text{years}$; mandatory annual mammograms ages $45-54\,\text{years}$; biennial/annual for ages $55+\,\text{years}$.
  • Clinical Breast Exam: Every $3\,\text{years}$ for ages $20-39\,\text{years}$; annually for ages $40+\,\text{years}$.
  • Colonoscopy: Baseline screening beginning at age $45\,\text{years}$.
  • Fecal Occult Blood Test (FOBT): Annually for all adults.
  • Digital Rectal Exam (DRE): Annually for males aged $50+\,\text{years}$.
• Tertiary Prevention: Lifestyle adjustments to prevent disease recurrence or secondary complications.

Seven Warning Signs of Cancer (CAUTION)

• C: Change in bowel or bladder habits.
• A: A sore that does not heal.
• U: Unusual bleeding or discharge.
• T: Thickening or lump in the breast or elsewhere.
• I: Indigestion or difficulty swallowing.
• O: Obvious change in a wart or mole.
• N: Nagging cough or hoarseness.

Cancer Treatments & Supportive Therapies

Surgical Interventions

• Prophylactic Surgery: Removes non-malignant tissue at risk of developing cancer (e.g., prophylactic mastectomy for BRCA gene mutations).
• Diagnostic Surgery: Biopsy excision to establish histological grading and tumor type.
• Curative Surgery: Total removal of localized cancerous tissue.
• Debulking Surgery: Partial resection of tumor bulk to increase efficacy of chemotherapy or radiation.
• Palliative Surgery: Performed to relieve distressing symptoms (e.g., bowel obstruction relief) without curative intent.
• Reconstructive/Restorative Surgery: Restores functional ability or cosmetic appearance.

Radiation Therapy

• External Beam Radiation (Teletherapy):
  • Radiation delivered from an external source.
  • Patient does not emit radiation and poses no danger to others.
  • Temporary skin markings must not be washed off or scrubbed.
• Internal Radiation (Brachytherapy):
  • Direct implantation of radioactive seeds/sources or systemic ingestion of unsealed isotopes.
  • Sealed Implant: Patient emits radiation, but bodily excretions are not radioactive.
  • Unsealed Isotope: Patient AND all bodily fluid excretions (sweat, urine, saliva) are radioactive.
  • Safety Rules: Place patient in a private room; wear a lead apron during care; wear a dosimeter film badge; limit visitors to $30\,\text{minutes/day}$ maintaining a $6\,\text{foot}$ distance; prohibit pregnant women or children from entering.
• Side Effects: Radiation dermatitis, severe fatigue, xerostomia, altered taste perception, bone marrow suppression.

Cytotoxic Systemic Chemotherapy

• Mechanisms & Administration:
  • Disrupts cell division throughout the systemic circulation; rapidly dividing normal cells (marrow, GI mucosal lining, hair follicles) are most damaged.
  • Dosing calculated strictly based on Body Surface Area (BSA in $m^2$).
  • Requires specialized Chemo-certified nurses for IV, intrathecal, intraperitoneal, or intra-arterial administration.
  • Personal Protective Equipment (PPE): Eye protection, double chemotherapy-rated gloves, non-permeable gown, and mask.
• Major Toxicities:
  • Bone Marrow Suppression: Anemia, Neutropenia (infection risk), Thrombocytopenia (bleeding risk).
  • Mucositis and Stomatitis: Painful ulceration along the GI tract.
  • Chemotherapy-Induced Nausea and Vomiting (CINV).
  • Alopecia, Cognitive Alterations ("Chemo Brain"), and Peripheral Neuropathy.

Pharmacological Management of CINV

• Serotonin Antagonists (e.g., ondansetron):
  • Blocks 5-$\text{HT}_3$ receptors in the chemoreceptor trigger zone (CTZ).
  • Side effects: Headache, diarrhea, QT interval prolongation (monitor ECG in cardiac disease).
• Substance P / Neurokinin-1 Antagonists (e.g., aprepitant):
  • Blocks neurokinin-1 receptors in the CNS.
  • Combined with dexamethasone and ondansetron for extended CINV control.
• Dopamine Antagonists (e.g., prochlorperazine, metoclopramide):
  • Blocks dopamine receptors in CTZ; metoclopramide promotes gastric emptying.
  • Side effects: Extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, anticholinergic effects.
• Cannabinoids (e.g., dronabinol):
  • Second-line CINV treatment and appetite stimulant.
  • Side effects: Dysphoria, dissociation, hypotension, tachycardia.
• Anticholinergics (e.g., scopolamine patch) & Antihistamines (e.g., dimenhydrinate):
  • Prevents motion-induced nausea; produces significant sedation and anticholinergic side effects.

Hematopoietic Growth Factors

• Erythropoietic Factors (e.g., epoetin alfa):
  • Stimulates RBC production for anemia.
  • Adverse Effects: Severe hypertension, deep vein thrombosis (DVT), stroke. Reduce dose once target Hgb reached.
• Leukopoietic Factors (e.g., filgrastim, pegfilgrastim):
  • Stimulates neutrophil production.
  • Adverse Effects: Bone pain, leukocytosis, splenomegaly/splenic rupture. Monitor WBC; withhold if WBC $> 100,000/mm^3$. Do not agitate vial.
• Thrombopoietic Factors (e.g., oprelvekin):
  • Stimulates platelet production.
  • Adverse Effects: Fluid retention, pulmonary edema, atrial fibrillation. Do not agitate vial.

Oncological Emergencies

• Sepsis & Disseminated Intravascular Coagulation (DIC): Widespread microvascular clotting followed by massive systemic hemorrhage secondary to severe neutropenia.
• Syndrome of Inappropriate Antidiuretic Hormone (SIADH): Excessive ADH causing dilutional hyponatremia; managed with fluid restriction and hypertonic saline.
• Spinal Cord Compression: Direct tumor pressure on the spinal cord; presents with back pain, motor weakness, and urinary/fecal incontinence. Managed with high-dose corticosteroids and radiation therapy.
• Hypercalcemia: Calcium release from bone metastasis; presents with muscle weakness, ECG changes, polyuria, anorexia, and confusion. Treated with aggressive hydration and calcitonin/bisphosphonates.
• Superior Vena Cava (SVC) Syndrome: SVC obstruction by tumor growth; produces facial edema, periorbital edema, distended neck/chest veins, and dyspnea. Emergency radiation therapy indicated.
• Tumor Lysis Syndrome (TLS): Rapid intracellular destruction of tumor cells releasing massive amounts of potassium, phosphorus, and uric acid into the bloodstream, producing severe acute kidney injury and fatal cardiac arrhythmias. Treated with hyperhydration, rasburicase, and allopurinol.

Leukemia & Hematopoietic Stem Cell Transplantation

Pathophysiology & Classification

• Uncontrolled proliferation of immature, non-functional white blood cells (blast cells) in the bone marrow.
• Overcrowding of bone marrow suppresses normal hematopoiesis, leading to:
  • Anemia (reduced RBC production)
  • Thrombocytopenia (reduced platelet production)
  • Leukopenia/Neutropenia (functional deficit of mature WBCs)
• Major Types:
  • Acute Myelogenous Leukemia (AML): Most common acute leukemia in adults.
  • Acute Promyelocytic Leukemia (APL): Subtype of AML; highly curable with specific targeted therapy.
  • Acute Lymphocytic Leukemia (ALL): Most common pediatric leukemia; accounts for $10\%$ of adult cases.
  • Chronic Myelogenous Leukemia (CML): Most common in adults $> 50\,\text{years}$; associated with Philadelphia chromosome.
  • Chronic Lymphocytic Leukemia (CLL): Most common chronic adult leukemia.

Clinical Manifestations

• Neurological: Headaches, sleepiness, decreased attention span, altered behavior, seizures, coma.
• Integumentary: Ecchymosis, petechiae, open non-healing skin lesions, pallor.
• Gastrointestinal: Bleeding gums, anorexia, weight loss, stool occult blood, hepatomegaly, splenomegaly.
• Renal: Hematuria.
• Musculoskeletal: Severe deep bone and joint pain.
• Cardiopulmonary: Resting tachycardia, orthostatic hypotension, dyspnea on exertion, heart murmurs, pulmonary infections.

Phases of Chemotherapy for Acute Leukemia

1. Induction Therapy: High-dose combination chemotherapy aimed at achieving rapid remission. Induces severe prolonged bone marrow aplasia. Requires strict protective neutropenic isolation in hospital for $4-6\,\text{weeks}$.
2. Consolidation Therapy: Repeated chemo courses or stem cell transplant to eliminate residual microscopic blast cells.
3. Maintenance Therapy: Low-dose oral/IV chemotherapy administered for months or years to maintain remission.

Hematopoietic Stem Cell Transplantation (HSCT)

• Donor Types: Autologous (patient's own stored cells), Syngeneic (identical twin), Allogeneic (HLA-matched relative or unrelated donor).
• Process Stages:
  1. Harvesting: Bone marrow aspirated surgically ($500-1000\,mL$ from iliac crest) OR Peripheral Blood Stem Cells (PBSC) collected via apheresis following filgrastim mobilization OR Umbilical Cord Blood.
  2. Conditioning: High-dose total body irradiation and lethal chemotherapy to destroy existing bone marrow and malignant cells.
  3. Transplantation: IV infusion of harvested stem cells through a central catheter.
  4. Engraftment: Transplanted stem cells take root in marrow cavities ($14-21\,\text{days}$ post-infusion). Success measured by tracking increasing donor chimerism levels.
• Post-HSCT Complications:
  • Severe pancytopenia
  • Graft-Versus-Host Disease (GVHD): Donor T-cells attack host tissues (skin, liver, GI tract).
  • Graft Failure: Fatal destruction or non-engraftment of donor tissue.
  • Sinusoidal Obstructive Syndrome (SOS / Veno-Occlusive Disease): Blockage of hepatic venules by fibrin and inflammation.

Nursing Interventions & Safety Protocols

• Infection Prevention (Neutropenic Precautions):
  • Private positive-pressure isolation room with HEPA filtration.
  • Monitor body temperature every $4\,\text{hours}$; fever ($> 100.4^\circ\text{F}$ / $38.0^\circ\text{C}$) is a medical emergency.
  • Eliminate fresh flowers, standing water, raw fruits, and raw vegetables.
• Bleeding Precautions:
  • Maintain bleeding precautions when platelets drop below $50,000/mm^3$.
  • Test all excretions for occult blood; measure abdominal girth daily to monitor for internal hemorrhage.
  • Avoid rectal temperatures, enemas, or IM injections.
• Home Safety Post-HSCT:
  • No live vaccines for the patient or household members for $2\,\text{years}$ post-HSCT.
  • Avoid crowds, domestic pets, and sick individuals.

Lymphoma

Classification & Pathophysiology

• Neoplastic proliferation of mature lymphocytes originating within lymphatic tissues.
• Hodgkin's Lymphoma (HL):
  • Peak incidence in teens/young adults and adults $> 50\,\text{years}$.
  • Linked to viral etiology (Epstein-Barr Virus, HTLV, HIV).
  • Characterized by the presence of Reed-Sternberg cells on tissue biopsy.
  • Originates in a single lymph node chain and spreads in an orderly, predictable manner.
• Non-Hodgkin's Lymphoma (NHL):
  • Includes $60+$ distinct subtypes; classified as B-cell or T-cell lymphomas.
  • Lacks Reed-Sternberg cells.
  • Spreads in a chaotic, unpredictable fashion to extra-nodal sites (bone marrow, CNS, testes).
  • Increased incidence in organ transplant recipients, HIV patients, and pesticide exposure.

Clinical Findings & Diagnostics

• Painless, enlarged, firm lymph nodes (typically cervical or supraclavicular).
• Systemic "B Symptoms": High fever, drenching night sweats, and unintentional weight loss ($> 10\%$ body mass).
• Generalized pruritus and severe fatigue.
• Diagnostics: Excisional lymph node biopsy (definitive), CT scans of chest/abdomen/pelvis, PET scan, bone marrow biopsy, elevated Lactate Dehydrogenase (LDH) and ESR.

Specialized Advanced Therapy & Care

• CAR T-Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy):
  • Patient T-cells are harvested, genetically modified to express synthetic CAR receptors targeting cancer antigens, expanded, and reinfused.
  • Complication: Cytokine Release Syndrome (CRS) - severe systemic inflammatory response occurring $5-7\,\text{days}$ post-infusion. Manifests as high fever, severe hypotension, pulmonary edema, disorientation, and multi-organ failure.
• Nursing Management:
  • Advise patients regarding sperm banking or oocyte cryopreservation prior to initiating therapy due to permanent infertility risks.
  • Educate regarding lifelong monitoring for secondary radiation-induced malignancies.

End of Life Care & Palliative Care

Palliative Care vs. Hospice Care

• Palliative Care: Provided at any stage of a serious illness; delivered concurrently with life-prolonging or curative therapies; no specific life-expectancy time restriction.
• Hospice Care: Offered specifically for terminally ill patients with a documented medical prognosis of $< 6\,\text{months}$ to live; curative interventions are discontinued; eligibility re-evaluated every $60-90\,\text{days}$.

Medicolegal Directives

• Advance Directive: Comprehensive written statement outlining personal healthcare preferences when decision-making capacity is lost.
• Do Not Resuscitate (DNR): Specific medical order prohibiting CPR or invasive resuscitation during cardiac or respiratory arrest.
• Durable Power of Attorney for Healthcare (DPOAHC): Designated legal surrogate proxy authorized to make medical decisions.
• Living Will: Directives regarding specific life-sustaining procedures desired during terminal states.

Approaching Death: Clinical Manifestations & Nursing Interventions

• Cool, Mottled, Cyanotic Extremities: Cover patient with light warm blankets; do not use electric warming blankets.
• Increased Somnolence / Sleep: Maintain a quiet environment; speak to patient directly using normal conversational tone.
• Reduced Intake of Food and Fluids: Do not force nutrition or fluid intake. Provide moist swabs for oral mucosa and lip balms.
• Incontinence: Provide meticulous skin care; consider indwelling urinary catheter solely for comfort.
• Secretion Congestion ("Death Rattle"): Lateral positioning to facilitate drainage; administer anticholinergic medications (e.g., atropine sublingual drops, hyoscyamine, scopolamine patch) to dry secretions.
• Cheyne-Stokes Respirations: Alternating hyperpnea and apnea. Elevate head of bed.
• Disorientation & Restlessness: Maintain calm lighting; administer low-dose benzodiazepines or neuroleptics if non-pharmacological soothing fails.

Postmortem Protocol

• Pronouncement: Auscultate apical heart sound for $1\,\text{full minute}$; assess for spontaneous carotid pulse and respirations; document precise time of death.
• Preparation: If no autopsy is ordered, remove all invasive lines, tubes, and catheters. Wash body, place clean linen, close eyelids, elevate head slightly on a pillow, and attach required identification tags.

Cystic Fibrosis

Genetic Pathophysiology

• Severe autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
• Leads to impaired transmembrane chloride and sodium transport.
• Produces exocrine gland dysfunction resulting in extremely thick, viscous, tenacious mucus secretions.
• Mucus plugs airways, pancreatic ducts, hepatic ducts, salivary glands, and reproductive tracts, causing progressive organ obstruction, atrophy, and chronic inflammation.
• Respiratory failure is the primary cause of mortality; average life expectancy is approximately $47\,\text{years}$.

Comprehensive Manifestations

• Pulmonary Findings: Chronic persistent cough, sputum production, recurrent bronchitis/abscesses, dyspnea, wheezing, intercostal retractions, clubbing of fingers, barrel chest, reduced FVC and $\text{FEV}_1$.
• Gastrointestinal & Metabolic Findings: Meconium ileus in newborns, foul-smelling greasy stools (steatorrhea), abdominal distention, failure to thrive, malnutrition, deficiencies in fat-soluble vitamins (Vitamins A, D, E, K), cystic fibrosis-related diabetes mellitus (CF-RD), rectal prolapse, salty-tasting skin.

Diagnostic Testing

• Sweat Chloride Test: Diagnostic gold standard; sweat chloride concentration between $60-200\,mEq/L$ confirms diagnosis (normal reference value is $< 40\,mEq/L$).
• Newborn Screening: Elevated Immunoreactive Trypsinogen (IRT) levels from heel-stick blood.

Management Protocols

• Airway Clearance Therapy: Daily chest physiotherapy (CPT) vest, manual percussion, postural drainage, Positive Expiratory Pressure (PEP) devices, and active cycle breathing.
• Medication Regimen: Inhaled bronchodilators, mucolytics (dornase alfa, hypertonic saline), inhaled antibiotics (tobramycin).
• CFTR Modulator Therapy: Ivacaftor (directly restores CFTR chloride channel function in specific targeted mutations).
• Gastrointestinal Care: Administer Pancreatic Enzyme Replacement Therapy (PERT - pancrelipase) immediately before or with every meal and snack. Provide high-calorie, high-protein nutrition with fat-soluble vitamin supplementation.
• Infection Control: Severe pulmonary infections frequently caused by Pseudomonas aeruginosa or Burkholderia cepacia. Patients with CF must maintain strict isolation from other CF patients to prevent cross-contamination.

Chronic Obstructive Pulmonary Disease (COPD)

Pathophysiology & Etiology

• Progressive lower respiratory disease characterized by persistent, irreversible airflow limitation.
• Emphysema:
  • Pollutants/tobacco smoke stimulate excessive protease activity, destroying alveolar elastin and septal walls.
  • Loss of elastic recoil leads to air trapping, hyperinflation of the lungs, flattening of the diaphragm, and severe ventilation-perfusion ($V/Q$) mismatching.
  • Anatomical Subtypes: Centrilobular (upper lobes; linked to smoking), Panlobular (entire acinus; linked to Alpha-1 Antitrypsin deficiency), and Paraseptal.
• Chronic Bronchitis:
  • Chronic hypersecretion of mucus and persistent inflammation of bronchi/bronchioles.
  • Characterized by mucosal edema, goblet cell hyperplasia, and chronic productive cough for at least $3\,\text{months}$ per year for $2\,\text{consecutive years}$.
• Primary Etiological Risk Factors: Tobacco smoking, passive smoke exposure, occupational dust/chemical exposures, and genetic Alpha-1 Antitrypsin (AAT) deficiency.

Clinical Manifestations

• Rapid, shallow respirations, dyspnea on exertion progressing to rest dyspnea
• Use of accessory respiratory muscles, tripod positioning, and pursed-lip breathing
• Barrel chest (increased anteroposterior-to-transverse ratio of $2:2$)
• Decreased chest expansion, hyper-resonant percussion notes
• Persistent cough with thick sputum production, chronic wheezing, and crackles
• Distended neck veins, dependent edema, and cyanosis (Cor Pulmonale)
• Clubbing of fingers, wasting of lean muscle mass, and $SpO_2 < 90\%$

GOLD Classification System (Based on Post-Bronchodilator $\text{FEV}_1$

• GOLD 1 (Mild): $\text{FEV}_1 \ge 80\%$ of predicted value.
• GOLD 2 (Moderate): $50\% \le \text{FEV}_1 < 80\%$ of predicted value.
• GOLD 3 (Severe): $30\% \le \text{FEV}_1 < 50\%$ of predicted value.
• GOLD 4 (Very Severe): $\text{FEV}_1 < 30\%$ of predicted value.

Laboratory & Diagnostic Evaluation

• Pulmonary Function Tests (PFTs): Confirms airflow limitation; demonstrates reduced $\text{FEV}_1/FVC$ ratio ($< 0.70$) and increased Residual Volume (RV).
• Arterial Blood Gases (ABGs): Chronic compensated respiratory acidosis with hypoxemia ($PaO_2 < 60\,mmHg$, $PaCO_2 > 45\,mmHg$, elevated HCO3).
• Complete Blood Count: Compensatory polycythemia (elevated Hgb/Hct due to chronic hypoxia).

Pharmacotherapy Regimen for COPD & Asthma

• Short-Acting Beta-Agonists (SABA - e.g., albuterol, levalbuterol):
  • Rescue bronchodilator. Rapid onset.
  • Side effects: Tachycardia, tremors, palpitations, anxiety.
• Long-Acting Beta-Agonists (LABA - e.g., salmeterol, formoterol):
  • Maintenance bronchodilator. Not for acute rescue.
• Inhaled Anticholinergics (e.g., ipratropium [short-acting], tiotropium [long-acting]):
  • Blocks muscarinic acetylcholine receptors, inducing bronchodilation and reducing secretions.
  • Side effects: Dry mouth, urinary retention, narrow-angle glaucoma exacerbation.
• Methylxanthines (e.g., theophylline):
  • Relaxes bronchial smooth muscle.
  • Narrow therapeutic range ($10-20\,mcg/mL$). Toxicity presents with severe vomiting, arrhythmias, and seizures. Avoid caffeine; smoking accelerates drug clearance.
• Inhaled Glucocorticoids (e.g., fluticasone, budesonide):
  • Reduces airway mucosal inflammation.
  • Patient must rinse mouth thoroughly after use to prevent oral candidiasis (thrush).
• Systemic Corticosteroids (e.g., oral prednisone):
  • Short-term exacerbation therapy.
  • Long-term side effects: Adrenal suppression, osteoporosis, hyperglycemia, peptic ulcer disease.
• Leukotriene Modifiers (e.g., montelukast, zafirlukast, zileuton):
  • Blocks leukotriene receptors. Zileuton/zafirlukast require liver enzyme monitoring. Montelukast carries a risk of neuropsychiatric events.
• Mast Cell Stabilizers (e.g., cromolyn):
  • Inhibits histamine release; nebulized maintenance therapy.
• Mucolytics (e.g., acetylcysteine) & Expectorants (e.g., guaifenesin):
  • Liquefies thick airway secretions.

Nursing Care & Management

• Oxygen Therapy: Titrate low-flow oxygen ($1-2\,L/min$ via nasal cannula or up to $40\%$ via Venturi mask) to maintain $SpO_2$ between $88\%-92\%$. Do not withhold oxygen in acute severe hypoxemia.
• Breathing Retraining: Teach pursed-lip breathing (inhale through nose, exhale slowly through pursed lips) and diaphragmatic breathing.
• Exercise Conditioning: Instruct patient to walk until dyspnea occurs, rest, and resume walking until achieving a cumulative total of $20\,\text{minutes}$.
• Dietary Adjustments: High-calorie, high-protein, low-carbohydrate small frequent meals (carbon dioxide is a byproduct of carbohydrate metabolism).

COVID-19

Etiology & Pathophysiology

• Caused by the SARS-CoV-2 single-stranded RNA virus.
• Transmitted via respiratory droplets, aerosols, and contact.
• Incubation period ranges from $2-14\,\text{days}$ post-exposure.
• Binds to ACE2 receptors in the lower respiratory tract, triggering systemic inflammatory cascades, endothelial dysfunction, hypercoagulability, and severe alveolar damage.

Clinical Manifestations

• Fever, chills, fatigue, generalized myalgias, and persistent headache
• Cough, shortness of breath, and dyspnea
• Sudden onset loss of taste (ageusia) or loss of smell (anosmia)
• Sore throat, nasal congestion, nausea, vomiting, abdominal pain, and diarrhea

Pharmacological Treatments

• Antiviral Therapies:
  • Paxlovid (nirmatrelvir with ritonavir): Oral treatment for mild-to-moderate infection in high-risk patients $12+\,\text{years}$; initiate within $5\,\text{days}$ of symptom onset.
  • Veklury (remdesivir): Intravenous antiviral infusion administered over $3\,\text{days}$; initiate within $7\,\text{days}$ of symptom onset.
  • Molnupiravir: Oral antiviral alternative for adults initiated within $5\,\text{days}$ of symptom onset.
• Supportive & Critical Care Treatments: Proning position to improve $V/Q$ matching, supplemental oxygen, dexamethasone, and prophylactic anticoagulation.
• Infection Control Precautions: Hospitalized patients require Special Airborne plus Contact Precautions (N95 respirator, face shield/eye protection, gown, double gloves, isolated negative-pressure room).

Asthma

Pathophysiology & Etiology

• Chronic inflammatory airway disorder characterized by reversible hyperresponsiveness, mucosal edema, bronchospasm, and mucus hypersecretion.
• Allergen exposure activates mast cells, basophils, and eosinophils, releasing histamine, leukotrienes, and bradykinin.
• Phenotypes:
  • Eosinophilic Asthma: Characterized by dense eosinophilic infiltration of airway mucosa ($50\%$ of cases).
  • Neutrophilic Asthma: Prominent neutrophilic inflammation; typically resistant to corticosteroids.
• Primary Triggers: Dust mites, pollen, pet dander, mold, cold dry air, respiratory viruses, NSAIDs/aspirin, exercise, GERD, and emotional stress.

Manifestations & Diagnostics

• Clinical Findings: Intermittent dyspnea, chest tightness, coughing, audible expiratory wheezing, tachypnea, intercostal retractions, cyanosis, and barrel chest (in severe long-standing cases).
• Diagnostic Measures: Pulmonary Function Tests show a $15\%-20\%$ increase in $\text{FEV}_1$ following bronchodilator administration. Elevated serum IgE and eosinophils in allergic phenotypes.

Status Asthmaticus

• Severe, life-threatening acute asthmatic exacerbation unresponsive to standard bronchodilator therapy.
• Clinical Signs: Extreme respiratory effort, accessory muscle overuse, distended neck veins, marked pulsus paradoxus.
• Emergency Intervention: Continuous nebulized albuterol, IV corticosteroids, IV magnesium sulfate, epinephrine, high-flow oxygen, and preparation for emergency intubation.
• Critical Warning Sign: Sudden cessation of wheezing ("silent chest") indicates complete airway obstruction and impending respiratory arrest, requiring emergent intervention.

Eating Disorders

Diagnostic Subtypes

• Anorexia Nervosa:
  • Persistent restriction of energy intake leading to significantly low body weight ($< 85\%$ of expected normal weight for age/height).
  • Intense fear of weight gain and distorted body image.
  • Subtypes: Restricting Type (dieting, fasting, excessive exercise) vs. Binge-Eating/Purging Type (self-induced vomiting, laxative/diuretic misuse).
• Bulimia Nervosa:
  • Recurrent episodes of binge eating followed by inappropriate compensatory behaviors (purging, excessive exercise, laxative abuse).
  • Frequency: Occurs at least once weekly for $3\,\text{months}$.
  • Body weight is typically within normal or slightly elevated BMI parameters.
  • Subtypes: Purging Type vs. Non-purging Type.
• Binge-Eating Disorder:
  • Recurrent intake of large quantities of food without compensatory purging behaviors.
  • Associated with loss of control, guilt, and obesity.
  • Frequency: Occurs at least once weekly for $3\,\text{months}$.
• Other Specific Disorders: Pica (eating non-nutritive substances), Rumination Disorder (regurgitation and re-chewing), ARFID (Avoidant/Restrictive Food Intake Disorder).

Systemic Assessment Findings

• Vital Signs: Hypothermia, severe bradycardia, hypotension, orthostasis.
• Integumentary: Lanugo (fine downy hair), pale extremities, dry skin, yellowed skin (hypercarotenemia), calluses over knuckles from self-induced vomiting (Russell's Sign).
• Head, Neck, Oral: Parotid gland enlargement (sialadenosis), severe dental enamel erosion and caries from gastric acid.
• Cardiovascular: Prolonged QT interval, dysrhythmias, peripheral edema, cardiomyopathy.
• Gastrointestinal: Constipation, severe laxative-induced diarrhea, esophageal tears (Mallory-Weiss), gastric rupture.
• Endocrine/Metabolic: Amenorrhea, metabolic alkalosis (from vomiting) or metabolic acidosis (from laxative abuse), hypokalemia, hyponatremia, hypophosphatemia.

Inpatient Criteria & Nursing Care

• Inpatient Admission Criteria: Body weight loss $> 20\%$ of ideal weight or body fat $< 10\%$, severe hypokalemia/electrolyte crisis, cardiac arrhythmias, severe bradycardia ($HR < 40\,\text{bpm}$), hypotension ($BP < 90/60\,mmHg$), hypothermia ($< 36.0^\circ\text{C}$), or acute psychiatric crisis.
• Refeeding Syndrome:
  • Fatal complication occurring when severely malnourished patients receive rapid nutritional re-introduction.
  • Pathophysiology: Insulin surge causes massive cellular uptake of glucose, driving phosphate, potassium, and magnesium intracellularly.
  • Results in severe hypophosphatemia, cardiac failure, pulmonary edema, seizures, and sudden death.
  • Prevention: Re-introduce calories slowly while strictly monitoring serum phosphorus, potassium, and magnesium.
• Inpatient Behavioral Protocols: Highly structured meal times ($30\,\text{minute}$ meal limits), constant supervision during and for $1\,\text{hour}$ after meals to prevent purging, strict weight monitoring upon awakening, and structured reward systems for targeted weight gains ($2-3\,lbs/week$).
• Pharmacotherapy: Fluoxetine (SSRI) used for anorexia and bulimia (takes $1-3\,\text{weeks}$ for initial response, $6-8\,\text{weeks}$ for peak effect).

Thyroid Disorders: Hypothyroidism & Hyperthyroidism

Endocrine Physiology

• Hypothalamic TRH stimulates Anterior Pituitary TSH, which stimulates the Thyroid gland to produce Thyroxine ($T_4$) and Triiodothyronine ($T_3$).
• Active hormone $T_3$ regulates basal metabolic rate.
• Serum $T_3/T_4$ and TSH operate via negative feedback.

Disease Comparison

Etiology

• Hypothyroidism: Primary (Hashimoto's autoimmune thyroiditis, radioiodine ablation, surgical thyroidectomy, iodine deficiency); Secondary (pituitary tumor); Tertiary (hypothalamic failure).
• Hyperthyroidism: Primary (Graves' disease - toxic diffuse goiter, toxic multinodular goiter, thyroiditis, excessive exogenous thyroid hormone therapy).

Manifestations

• Hypothyroidism: Extreme fatigue, lethargy, cold intolerance, weight gain, constipation, depression, brittle nails, thinning hair, dry skin, facial/periorbital edema, bradycardia, hypotension, hypoventilation, hoarse voice, menorrhagia.
• Hyperthyroidism: Hyperactivity, nervousness, heat intolerance, weight loss despite increased appetite, frequent bowel movements/diarrhea, warm moist flushed skin, fine tremors, tachycardia, palpitations, dysrhythmias (atrial fibrillation), exophthalmos (Graves' prominent bulging eyes), goiter.

Diagnostics

• Hypothyroidism: Low serum $T_3$ and $T_4$; High TSH (primary disease).
• Hyperthyroidism: High serum $T_3$ and $T_4$; Low TSH (primary disease); elevated Thyroid-Stimulating Immunoglobulins (TSI in Graves').

Severe Crises

• Hypothyroidism: Myxedema Coma - Life-threatening crisis. Manifests as severe hypothermia, extreme bradycardia, hypotension, hypoventilation, hyponatremia, hypoglycemia, and coma. Administer IV levothyroxine, IV hydrocortisone, and mechanical ventilation.
• Hyperthyroidism: Thyroid Storm / Thyrotoxic Crisis - Fatal crisis triggered by stress, trauma, or infection. Manifests as hyperpyrexia ($> 101.3^\circ\text{F}$ / $38.5^\circ\text{C}$), extreme tachycardia, delirium, high-output HF, and tremors. Administer thionamides, Lugol's solution, IV beta blockers, and cooling blankets. Do not administer aspirin (displaces thyroid hormone from binding proteins).

Pharmacotherapy Regimen

• Levothyroxine (Synthroid):
  • Synthetic $T_4$ replacement.
  • Take once daily in the morning on an empty stomach with a full glass of water, at least $30-60\,\text{minutes}$ before breakfast.
  • Enhances effects of warfarin; increases requirements for insulin and digoxin.
• Thionamides (Methimazole / Propylthiouracil - PTU):
  • Inhibits thyroid hormone synthesis. PTU also prevents peripheral conversion of $T_4$ to $T_3$.
  • Side Effects: Agranulocytosis (instruct patient to report fever or sore throat immediately) and hepatotoxicity.
• Lugol's Solution (Potassium Iodide):
  • Inhibits thyroid hormone release and reduces vascularity prior to thyroidectomy.
  • Administer $1\,\text{hour}$ after thionamides. Dilute in juice and drink through a straw to prevent tooth discoloration.
• Radioactive Iodine ($^{131}\text{I}$):
  • Destroys thyroid parenchyma cells.
  • Radiation Precautions: Avoid close contact with pregnant women and children for $1\,\text{week}$; flush toilet twice; use separate utensils.

Adrenal Disorders: Cushing's Disease & Addison's Disease

Adrenal Physiology

• Pituitary ACTH stimulates the Adrenal Cortex to release:
  • Mineralocorticoids (Aldosterone): Promotes renal sodium and water reabsorption and potassium excretion.
  • Glucocorticoids (Cortisol): Controls glucose, fat, and protein metabolism, suppresses immune response, modulates stress response.
  • Sex Steroids (Androgens/Estrogens).

Cushing's Disease / Cushing's Syndrome

• Pathophysiology: Hypercortisolism. Cushing's Disease is caused by endogenous pituitary ACTH-secreting tumors or adrenal adenomas. Cushing's Syndrome is caused by exogenous therapeutic corticosteroid administration.
• Clinical Findings: Muscle wasting in extremities, truncal obesity, "moon face," "buffalo hump," purple abdominal striae, fragile skin, easy bruising/petechiae, hirsutism, acne, hypertension, hyperglycemia, hypokalemia, hypocalcemia, hypernatremia, susceptibility to infection, and osteoporosis/pathological fractures.
• Diagnostics: Elevated 24-hour urinary free cortisol, elevated salivary cortisol, failure to suppress cortisol following Dexamethasone Suppression Test, elevated plasma ACTH (in pituitary origin).
• Surgical Interventions: Hypophysectomy (transsphenoidal resection of pituitary tumor) OR Adrenalectomy.
  • Post-Hypophysectomy Nursing Care: Monitor nasal drainage for CSF leak (test fluid for glucose; check for "halo sign"); instruct patient to avoid brushing teeth for $2\,\text{weeks}$; avoid coughing, sneezing, or bending at the waist (prevents elevated ICP).
• Pharmacotherapy: Ketoconazole (inhibits corticosteroid synthesis; monitor liver enzymes), Mitotane (adrenocortical cytotoxic agent), Hydrocortisone replacement.

Addison's Disease (Adrenocortical Insufficiency)

• Pathophysiology: Hypocortisolism and hypoaldosteronism. Primary Addison's is caused by autoimmune destruction of adrenal cortex, TB, HIV, or bilateral adrenalectomy. Secondary Addison's is caused by abrupt withdrawal of exogenous steroid therapy or pituitary failure.
• Clinical Findings: Severe fatigue, muscle weakness, weight loss, anorexia, nausea, vomiting, salt cravings, hyperpigmentation of skin and mucous membranes (bronzing - primary disease), hypotension, orthostasis, hyponatremia, hyperkalemia, hypercalcemia, and hypoglycemia.
• Diagnostics: ACTH Stimulation Test (plasma cortisol measured $30$ and $60\,\text{minutes}$ post IV ACTH injection; failure of cortisol to rise confirms primary Addison's).
• Addisonian Crisis (Acute Adrenal Insufficiency):
  • Life-threatening emergency triggered by stress, illness, trauma, or steroid withdrawal.
  • Manifestations: Severe hypotension, circulatory shock, severe hypoglycemia, hyperkalemia, dysrhythmias, hyponatremia, and severe abdominal/back pain.
  • Interventions: Immediate IV bolus of hydrocortisone ($100\,mg$); rapid IV fluid resuscitation ($0.9\%$ Normal Saline or $D_5NS$); IV dextrose for hypoglycemia; IV insulin with dextrose, loop diuretics, or sodium polystyrene sulfonate for hyperkalemia; place patient in Trendelenburg position.
• Maintenance Pharmacotherapy: Hydrocortisone (oral glucocorticoid replacement; dose must be doubled/tripled during periods of stress, illness, or trauma) and Fludrocortisone (oral mineralocorticoid replacement; monitor BP and serum sodium/potassium).

Celiac Disease

Pathophysiology & Etiology

• Autoimmune gastrointestinal disorder characterized by severe chronic inflammation of the small intestine mucosal lining upon ingestion of gluten proteins (found in wheat, rye, barley, bulgur, durum, farina, malt, semolina, and spelt).
• Ingestion triggers immune-mediated destruction and flattening of small intestinal villi, producing severe malabsorption.

Clinical Findings

• Gastrointestinal: Chronic diarrhea, steatorrhea (foul, bulky, fatty stools), abdominal distention, flatulence, abdominal pain, weight loss, anorexia, vomiting, lactose intolerance.
• Systemic/Extra-intestinal: Anemia (iron and folate deficiency), osteoporosis, joint pain, aphthous stomatitis, dermatitis herpetiformis, muscle wasting, early menopause, infertility.

Diagnostic Criteria

• IgA Anti-Tissue Transglutaminase (tTG) Antibodies: Positive (patient MUST remain on a gluten-containing diet prior to blood test).
• Endoscopy (EGD) with Small Intestinal Biopsy: Gold standard; demonstrates villous atrophy and crypt hyperplasia.
• Genetic Testing: Identifies HLA-DQ2 or HLA-DQ8 gene loci.

Management

• Strict lifelong Gluten-Free Diet (GFD): Completely eliminate wheat, rye, barley, and contaminated oats. Allowable grains include rice, corn, quinoa, tapioca, and buckwheat.
• Supplementation: Provide fat-soluble vitamins, iron, and folate.

Tuberculosis

Pathophysiology & Transmission

• Infectious granulomatous disease caused by the acid-fast bacillus Mycobacterium tuberculosis.
• Transmission: Airborne droplets produced by coughing, sneezing, or talking.
• Inhaled bacilli lodge in alveolar spaces, eliciting a local inflammatory response forming Ghon tubercle complexes. Primary infection may resolve into Latent TB Infection (LTBI - enclosed bacteria, asymptomatic, non-contagious).
• Secondary/Reactivation TB: Occurs when host immunity wanes, causing caseous necrosis, cavitary lung destruction, and systemic hematogenous dissemination (Miliary TB).

Manifestations & Risk Factors

• Risk Factors: Constant close contact with infected individuals, immunocompromised states (HIV), crowded institutional settings (prisons, homeless shelters, long-term care facilities), IV drug use, alcoholism, and travel to endemic regions.
• Clinical Findings: Progressive fatigue, lethargy, anorexia, unintended weight loss, low-grade afternoon fever, drenching night sweats, persistent cough lasting $> 3\,\text{weeks}$, mucopurulent sputum production, hemoptysis, and dull chest pain.

Diagnostic Protocols

• Mantoux Tuberculin Skin Test (TST / PPD):
  • Intradermal injection of $0.1\,mL$ purified protein derivative; read $48-72\,\text{hours}$ later.
  • Measured by the transverse diameter of palpable induration (hardness) in millimeters (not erythema).
  • Induration Cutoffs:
  • $\ge 5\,mm$: Positive for high-risk individuals (HIV-infected, recent TB contact, fibrotic chest X-ray changes, organ transplant recipients).
  • $\ge 10\,mm$: Positive for moderate-risk individuals (recent immigrants from high-prevalence areas, injection drug users, residents/employees of high-risk congregate settings, children $< 5\,\text{years}$).
  • $\ge 15\,mm$: Positive for all individuals with no known risk factors.
  • False positives occur in individuals who received the Bacille Calmette-Guérin (BCG) vaccine. Anergy (inability to mount an immune response) produces false negatives in severe immunocompromise.
• QuantiFERON-TB Gold / T-SPOT: Interferon-gamma release assay (IGRA) blood test; unaffected by BCG vaccination status.
• Acid-Fast Bacilli (AFB) Sputum Smear and Culture: Sputum culture confirms active disease diagnosis. Three consecutive negative AFB morning sputum cultures are required to declare a patient non-infectious.
• Chest X-Ray: Identifies active cavitary lesions, Ghon complexes, or pleural effusions.

Pharmacotherapy Regimen (RIPE Therapy)

• Isoniazid (INH):
  • Adverse Effects: Severe hepatotoxicity and peripheral neuropathy.
  • Interventions: Co-administer Vitamin $B_6$ (pyridoxine) to prevent neuropathy. Avoid alcohol and tyramine-containing foods. Monitor liver function tests (LFTs).
• Rifampin (RIF):
  • Adverse Effects: Hepatotoxicity, gastrointestinal distress, and orange/red discoloration of bodily fluids (tears, sweat, urine).
  • Interventions: Advise patient that soft contact lenses will stain permanently. Reduces effectiveness of oral contraceptives, warfarin, and HIV protease inhibitors.
• Pyrazinamide (PZA):
  • Adverse Effects: Hepatotoxicity and hyperuricemia/gout.
• Ethambutol (EMB):
  • Adverse Effects: Optic neuritis (decreased visual acuity and loss of red-green color discrimination). Test baseline visual acuity and color vision monthly.

Nursing Isolation Precautions

• Place patient in an Airborne Infection Isolation Room (AIIR) with negative air pressure ($\ge 12$ air exchanges per hour).
• Healthcare workers must wear an N95 respirator mask.
• Patient must wear a surgical mask during transport outside the negative pressure room.
• Enforce Directly Observed Therapy (DOT) for non-compliant patients.

Osteomyelitis

Etiology & Pathophysiology

• Severe, painful infection of the bone tissue and bone marrow, most commonly caused by Staphylococcus aureus.
• Mechanisms:
  • Exogenous (Direct Inoculation): Microorganisms enter via open fracture, penetrating wound, or surgical hardware insertion.
  • Endogenous (Hematogenous): Microorganisms blood-borne from a distant infection site (e.g., severe UTI, central venous catheter infection, endocarditis).
  • Contiguous: Spread from adjacent soft tissue infections (e.g., diabetic foot ulcers, vascular insufficiency ulcers).
• Pathodynamic Process: Inflammation produces vascular leakage, edema, and pus accumulation within unyielding bone tissue. Vessel thrombosis leads to bone ischemia and necrosis, creating isolated dead bone segments (Sequestrum). New reactive bone formation (Involucrum) encapsulates the sequestrum, preventing antibiotic penetration.

Manifestations & Diagnostics

• Acute Osteomyelitis: Localized bone pain worsening with movement; localized erythema, swelling, warmth, tenderness; systemic fever, chills, leukocytosis, elevated ESR and C-Reactive Protein (CRP).
• Chronic Osteomyelitis: Persistent sinus tract drainage, ulceration, localized swelling, absent fever.
• Diagnostics: Plain Radiographs, Magnetic Resonance Imaging (MRI - gold standard for soft tissue and marrow necrosis), Blood Cultures, Bone Biopsy/Wound Cultures.

Pharmacotherapy & Surgical Management

• Long-Term Antibiotic Therapy: Minimum $4-6\,\text{weeks}$ for acute osteomyelitis; $3+\,\text{months}$ for chronic osteomyelitis. Administered via Peripherally Inserted Central Catheter (PICC).
• Drug Regimens:
  • Vancomycin: Glycopeptide. Monitor trough levels before 4th dose. Infuse over at least $1\,\text{hour}$ to prevent "Red Man Syndrome" (flushing, severe hypotension). Monitor BUN and creatinine for nephrotoxicity.
  • Fluoroquinolones (e.g., ciprofloxacin): Risk of Achilles tendon rupture and phototoxicity. Do not take with dairy/calcium.
  • Linezolid: Used for VRE. Avoid tyramine-containing foods; monitor CBC for pancytopenia.
  • Carbapenems / Cephalosporins / Clindamycin / Trimethoprim-Sulfamethoxazole.
• Surgical Interventions: Incision and drainage, surgical sequestrectomy, bone grafting, hyperbaric oxygen therapy ($100\%$ oxygen accelerates tissue healing), or amputation.

Personality Disorders

Cluster Classification Criteria

• Cluster A (Odd or Eccentric Traits):
  • Paranoid: Distrust, pervasive suspiciousness, hypervigilance, belief that others intend to exploit or deceive.
  • Schizoid: Emotional detachment, indifference to social relationships, solitary preference, flat affect.
  • Schizotypal: Magical thinking, odd beliefs, perceptual distortions, eccentric appearance, severe social anxiety.
• Cluster B (Dramatic, Emotional, or Erratic Traits):
  • Antisocial: Disregard for rights of others, lack of empathy, deceitfulness, impulsivity, criminality, verbal charm.
  • Borderline: Unstable affect, identity disturbances, intense fear of abandonment, chronic feelings of emptiness, splitting defense mechanism, self-mutilation, recurrent suicidal behavior.
  • Histrionic: Attention-seeking behavior, extreme seductiveness, dramatic emotional expression, easily influenced.
  • Narcissistic: Grandiosity, extreme need for admiration, total lack of empathy, entitlement, sensitivity to criticism.
• Cluster C (Anxious or Fearful Traits):
  • Avoidant: Extreme fear of rejection/humiliation, social inhibition, feelings of inadequacy, desires relationships but avoids contact.
  • Dependent: Submissive behavior, excessive need to be taken care of, fear of separation, difficulty making daily decisions independently.
  • Obsessive-Compulsive Personality Disorder: Extreme preoccupation with orderliness, perfectionism, control, and rigidity (lacks true obsessions/compulsions seen in OCD).

Ego Defense Mechanisms

• Suppression: Voluntary denial of unpleasant thoughts or situations.
• Repression: Unconscious exclusion of painful ideas from awareness.
• Regression: Reverting to developmental behaviors from an earlier age.
• Displacement: Transferring emotional reactions from one object/person to a neutral substitute.
• Reaction Formation: Expressing the exact opposite behavior of unacceptable underlying drives.
• Undoing: Performing acts to symbolically cancel out past unacceptable behaviors.
• Rationalization: Justifying illogical behaviors with acceptable explanations.
• Dissociation: Compartmentalizing traumatic memories away from conscious awareness.
• Denial: Refusing to acknowledge the reality of a situation.
• Splitting: Inability to integrate positive and negative qualities of self or others into a cohesive image; viewing people as entirely good or entirely evil (common in Borderline Personality Disorder).
• Projection: Attributing one's own unacceptable feelings or impulses onto another individual.

Nursing Management

• Set clear, firm, consistent boundaries with Cluster B patients to prevent manipulation and splitting behavior.
• Maintain absolute safety precautions for patients demonstrating self-injurious or suicidal ideations.
• Implement milieu therapy and encourage healthy emotional expression.

Obsessive-Compulsive Disorder (OCD)

Clinical Pathophysiology

• Characterized by persistent, distressing, intrusive, unwanted thoughts, urges, or images (Obsessions) and/or repetitive, rigid, purposeful behaviors or mental acts performed to reduce obsession-induced anxiety (Compulsions).
• Compulsive rituals consume at least $1\,\text{hour}$ per day, causing significant social, occupational, and functional impairment.

Common Obsessions & Compulsions

• Obsessions: Fear of contamination, fear of harm to self/others, desire for absolute symmetry/order, intrusive aggressive or religious thoughts.
• Compulsions: Repetitive handwashing, excessive cleaning, counting rituals, checking locks/appliances repeatedly, ordering items.

Treatment & Nursing Protocols

• Behavioral Therapies: Cognitive Behavioral Therapy (CBT) combined with Exposure and Response Prevention (ERP - gradually exposing patient to anxiety-inducing stimuli while preventing performance of compulsive rituals).
• Pharmacotherapy: High-dose SSRIs (e.g., fluoxetine, sertraline, fluvoxamine) or tricyclic antidepressants (clomipramine).
• Advanced Therapies: Deep Brain Stimulation (DBS) or Transcranial Magnetic Stimulation (TMS).
• Nursing Care: Initially allow the patient sufficient time to complete compulsive rituals to avoid panic; gradually limit time allotted for rituals as coping mechanisms develop. Do not interrupt rituals abruptly without a supportive safety plan.

Cirrhosis

Pathophysiology & Etiology

• Extensive, irreversible scarring and nodular regeneration of liver parenchyma.
• Chronic inflammation causes cell necrosis, fibrotic band formation, structural distortion of lobules, and compression of central veins and portal capillaries.
• Major Subtypes: Postnecrotic (caused by chronic viral hepatitis C or B), Laënnec's / Alcoholic (caused by chronic alcoholism), Biliary / Cholestatic (caused by chronic biliary obstruction).

Systemic Manifestations

• Integumentary: Jaundice, scleral icterus, pruritus (bile salt accumulation), palmar erythema, spider angiomas (face, neck, chest), petechiae, ecchymosis.
• Gastrointestinal & Abdominal: Abdominal pain, fetor hepaticus (fruity/musty breath odor), ascites, caput medusae (dilated abdominal veins), hepatomegaly, splenomegaly.
• Neurological: Asterixis ("liver flap" coarse hand tremors), hepatic encephalopathy, memory loss, coma.
• Endocrine/Metabolic: Gynecomastia, testicular atrophy, amenorrhea, hyperaldosteronism (fluid retention).

Laboratory Diagnostic Metrics

• Serum Liver Enzymes: AST, ALT, LDH, ALP, and GGT are elevated.
• Serum Bilirubin: Significantly elevated.
• Total Serum Protein & Albumin: Significantly low (due to impaired hepatic synthesis).
• Serum Ammonia: Elevated.
• Prothrombin Time (PT) & INR: Significantly prolonged (impaired synthesis of Factors II, VII, IX, X).
• Platelets: Low (thrombocytopenia secondary to hypersplenism).

Severe Complications

• Portal Hypertension: Increased pressure within the portal venous system ($> 5\,mmHg$ above normal) due to intrahepatic obstruction. Leads to splenomegaly, ascites, esophageal varices, and hemorrhoids.
• Ascites: Third-spacing of fluid into the peritoneal cavity caused by portal hypertension, splanchnic arterial vasodilation, and hypoalbuminemia.
  • Management: Low-sodium diet ($1-2\,g/day$), spironolactone paired with furosemide, daily weights, abdominal girth measurements. Perform Paracentesis (have patient void prior to procedure; position upright in high-Fowler's; monitor for hypovolemic shock; re-infuse IV albumin post-procedure).
• Esophageal Varices: Fragile, distended veins in the submucosa of the lower esophagus. High risk of massive rupture and exsanguination.
  • Management: Nonselective beta blockers (propranolol) to lower portal pressure. Acute Bleeding: Emergency Octreotide IV infusion (causes splanchnic vasoconstriction), Endoscopic Band Ligation (EBL), or Sengstaken-Blakemore tube insertion (balloon tamponade).
• Hepatic Encephalopathy (Portal-Systemic Encephalopathy):
  • Neuropsychiatric syndrome caused by buildup of toxic circulating ammonia and GABA crossing the blood-brain barrier.
  • Stages: Stage 1 (mild confusion, sleep disturbance); Stage 2 (lethargy, asterixis, personality changes); Stage 3 (stupor, marked confusion, incoherent speech); Stage 4 (comatose).
  • Pharmacotherapy: Lactulose (promotes ammonia excretion via bowel; titrate to achieve $2-3$ soft stools daily; side effects: abdominal cramping, diarrhea) and Rifaximin (intestinal non-absorbable antibiotic to reduce ammonia-producing gut bacteria).
• Additional Complications: Hepatorenal Syndrome (progressive renal failure secondary to hepatic failure), Spontaneous Bacterial Peritonitis (SBP - fever, abdominal pain; treated with IV cefotaxime), Hepatopulmonary Syndrome.

Seizure Disorders

Pathophysiology & Classification

• Seizure: Paroxysmal, excessive, uncontrolled electrical discharges of central nervous system neurons.
• Epilepsy: Chronic neurological disorder defined by two or more unprovoked seizures.
• Classification:
  • Generalized Seizures (Involves Both Hemispheres):
  • Tonic: Sudden loss of consciousness, abrupt increase in muscle tone/stiffness, autonomic signs; lasts $30\,\text{seconds}$ to several minutes.
  • Clonic: Rhythmic, bilateral muscle jerking/clonus, tongue biting, incontinence; lasts several minutes.
  • Tonic-Clonic (Grand Mal): Sequence of tonic contraction followed by clonic jerking, ending in a postictal state (fatigue, severe confusion, amnesia).
  • Myoclonic: Brief, shock-like muscle contraction of extremities.
  • Atonic (Drop Attacks): Sudden total loss of muscle tone causing immediate collapse; high fall risk.
  • Focal / Partial Seizures (Originates in One Hemisphere):
  • Complex Partial: Impaired consciousness, automatisms (lip smacking, chewing, wandering), postictal confusion.
  • Simple Partial: Consciousness preserved; focal motor activity, sensory visual/auditory distortions, autonomic signs, or aura.

Etiology & Triggers

• Primary (Idiopathic): Genetic predisposition.
• Secondary: Head trauma, brain tumors, stroke, severe fever (febrile seizures), metabolic derangements (hypoglycemia, hyponatremia), acute alcohol or sedative withdrawal, central nervous system infections (meningitis), or antiepileptic drug non-adherence.

Antiepileptic Pharmacotherapy (AEDs)

• Phenytoin (Dilantin):
  • Inhibits voltage-gated sodium channels.
  • Therapeutic Serum Level: $10-20\,mcg/mL$.
  • Adverse Effects: Gingival hyperplasia (instruct patient on meticulous dental hygiene and folic acid), nystagmus, ataxia, hirsutism, Stevens-Johnson Syndrome (SJS), osteomalacia (disrupts Vitamin D/K metabolism).
  • Decreases efficacy of warfarin and oral contraceptives.
• Carbamazepine (Tegretol):
  • Adverse Effects: Visual disturbances, blood dyscrasias (leukopenia, aplastic anemia, thrombocytopenia), hyponatremia/SIADH, and SJS.
  • Avoid grapefruit juice.
• Valproic Acid (Depakote):
  • Adverse Effects: Severe hepatotoxicity, fatal pancreatitis, thrombocytopenia, hyperammonemia, and neural tube defects (teratogenic).
• Barbiturates (Phenobarbital):
  • Produces CNS depression. Risk of dependence, respiratory depression, and severe sedation.

Complications & Emergency Management

• Status Epilepticus:
  • Medical emergency defined as a continuous seizure lasting $> 5\,\text{minutes}$ OR recurrent seizures over $30\,\text{minutes}$ without recovery of consciousness.
  • Results in brain hypoxia, severe metabolic acidosis, hyperthermia, rhabdomyolysis, and brain death.
  • Immediate Interventions: Establish airway, administer oxygen, obtain IV access; administer IV First-Line Benzodiazepines (lorazepam or diazepam); follow with IV loading doses of phenytoin, fosphenytoin, or levetiracetam.
• Sudden Unexpected Death in Epilepsy (SUDEP): Fatal non-traumatic event in epilepsy patients.
• Nursing Seizure Precautions: Maintain oxygen and suction at bedside, pad side rails, establish IV access. During seizure: Position patient on their side (lateral recumbent), protect head, loosen clothing, do not insert any object into the mouth, do not restrain, time the seizure duration, and monitor postictal recovery.

Urinary Tract Infections & Pyelonephritis

Pathophysiology & Etiology

• Urinary Tract Infection (UTI):
  • Bacterial invasion of lower urinary tract structures (urethra, bladder, prostate).
  • Primary Pathogen: Escherichia coli ($> 80\%$ of cases).
  • Classifications: Uncomplicated (involves normal healthy non-pregnant female bladder) vs. Complicated (involves structural/functional abnormalities, indwelling catheters, neurogenic bladder, pregnancy, diabetes, or male gender).
  • Recurrent UTI: $\ge 2$ infections in $6\,\text{months}$ OR $\ge 3$ in $1\,\text{year}$.
• Pyelonephritis:
  • Acute or chronic inflammatory infection of the renal parenchyma and renal pelvis.
  • Results from ascending lower urinary tract infection or vesicoureteral reflux.
  • Repeated chronic episodes produce fibrotic renal scarring, tubular destruction, and Chronic Kidney Disease.

Systemic Manifestations

• Lower UTI (Cystitis): Dysuria, urinary frequency, urgency, suprapubic discomfort/pain, hematuria, pyuria, nocturia, incomplete bladder emptying. Older adults present with confusion, mental status changes, and vague abdominal discomfort.
• Pyelonephritis: High fever, chills, tachycardia, tachypnea, severe flank pain, Costovertebral Angle (CVA) tenderness, nausea, vomiting, malaise, abdominal pain, plus cystitis symptoms.

Diagnostic Evaluation

• Urinalysis: Positive Leukocyte Esterase, positive Nitrates, presence of WBCs, RBCs, and bacteria.
• Urine Culture & Sensitivity: Identifies specific organism ($> 10^5\,\text{CFU/mL}$ confirms diagnosis).
• Complete Blood Count: Leukocytosis with left shift (in pyelonephritis).
• Diagnostic Imaging: KUB X-ray, CT scan of abdomen/pelvis.

Pharmacotherapy Regimen

• Antibiotics for Lower UTI: Nitrofurantoin, Trimethoprim-Sulfamethoxazole, Fosfomycin.
• Urinary Analgesic: Phenazopyridine (Azo) - Relieves dysuria. Educate patient that urine will turn bright red-orange.
• Catheter-Associated UTI (CAUTI) Prevention: Maintain closed drainage system, secure catheter, keep drainage bag below bladder level, perform routine perineal care, remove catheter immediately when no longer clinically indicated.

Glomerulonephritis & Nephrotic Syndrome

Pathophysiology

• Acute Glomerulonephritis:
  • Immune complex-mediated inflammation of glomerular capillaries, commonly developing $1-2\,\text{weeks}$ following a Group A Beta-Hemolytic Streptococcus infection (Post-Streptococcal Glomerulonephritis) or systemic disease (Lupus).
  • Antigen-antibody complexes trap within glomerular basement membranes, triggering complement activation, hypercellularity, capillary lumen obliteration, and marked reduction in Glomerular Filtration Rate (GFR).
• Nephrotic Syndrome:
  • Glomerular disorder characterized by severe increased glomerular capillary permeability to plasma proteins.
  • Massive loss of protein in urine (Proteinuria) leads to severe Hypoalbuminemia. Lowered oncotic pressure drives fluid into interstitial spaces, producing massive systemic edema (Anasarca) and triggering hepatic synthesis of lipids (Hyperlipidemia).
  • Causes: Minimal Change Disease (primary pediatric cause), Diabetes Mellitus, Systemic Lupus Erythematosus.

Clinical Manifestations

• Acute Glomerulonephritis: Periorbital/facial edema upon awakening, generalized dependent edema, dark tea-colored/cola-colored hematuria, mild-to-moderate proteinuria, hypertension, oliguria, pulmonary congestion (crackles, dyspnea, $S_3$), uremic signs (asterixis, slurred speech).
• Nephrotic Syndrome: Massive foamy/frothy urine, severe dependent pitting edema, facial/periorbital edema, rapid weight gain, hypertension, hyperlipidemia, lipiduria, hypercoagulability/thromboembolism (due to loss of antithrombin III in urine).

Diagnostic Metrics

• Urinalysis: Glomerulonephritis shows dysmorphic RBCs, RBC casts, moderate protein. Nephrotic Syndrome shows massive proteinuria ($> 3.5\,g/24\,hours$).
• Blood Tests: Glomerulonephritis shows elevated BUN/creatinine, reduced GFR, elevated Anti-Streptolysin O (ASO) titer. Nephrotic Syndrome shows severe hypoalbuminemia ($< 3.0\,g/dL$) and hypercholesterolemia.

Interventions & Pharmacotherapy

• Acute Glomerulonephritis Management: Administer antibiotics (penicillin) for active streptococcal infection, antihypertensives, loop diuretics, fluid and sodium restrictions, and low-to-moderate protein diet. Monitor daily weights and blood pressure.
• Nephrotic Syndrome Management: Administer corticosteroids (prednisone) to suppress glomerular inflammation, immunosuppressants (cyclophosphamide, cyclosporine), ACE inhibitors (reduces intraglomerular pressure and proteinuria), loop diuretics, lipid-lowering statins, and anticoagulants (heparin) to prevent renal vein thrombosis.

Systemic Lupus Erythematosus (Lupus)

Pathophysiology & Etiology

• Chronic, progressive, multisystem autoimmune inflammatory connective tissue disorder.
• Autoantibodies (specifically Antinuclear Antibodies - ANA) form immune complexes that deposit within tissues and blood vessel walls throughout the body, triggering Type III hypersensitivity reactions.
• Produces widespread vasculitis, tissue necrosis, and progressive multi-organ failure.
• Predominantly affects females ($90\%$ of cases) aged $15-44\,\text{years}$; higher prevalence in Black, Hispanic, and Asian women.
• Disease pattern characterized by unpredictable exacerbations (flares) and remissions.

Systemic Manifestations

• Integumentary: Erythematous macular facial eruption across bridge of nose and cheeks ("Butterfly Rash" / malar rash), discoid skin lesions, photosensitivity (severe rash upon sunlight exposure), alopecia, oral/nasopharyngeal mucosal ulcers.
• Musculoskeletal: Polyarthralgia, non-erosive inflammatory arthritis, joint swelling, morning stiffness.
• Cardiovascular/Pulmonary: Pericarditis, myocarditis, Raynaud's phenomenon (vasospasm of digits causing tricolor changes: pallor to cyanosis to rubor), pleuritis, pleural effusion.
• Renal: Lupus Nephritis (glomerular damage leading to proteinuria, hematuria, hypertension, renal failure; leading cause of death).
• Neurological: Psychosis, seizures, peripheral neuropathy, cognitive dysfunction.
• Hematologic: Hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia.

Diagnostic Criteria & Laboratory Findings

• Antinuclear Antibodies (ANA): Positive in $> 95\%$ of patients.
• Anti-Double-Stranded DNA (anti-dsDNA) & Anti-Smith (anti-SM) Antibodies: Highly specific for SLE.
• Serum Complement (C3 and C4): Decreased during active flares (consumed by immune complex deposition).
• Inflammatory Markers: Elevated ESR and CRP.

Pharmacotherapy Regimen

• Disease-Modifying Antirheumatic Drugs (DMARDs):
  • Hydroxychloroquine: Antimalarial/immunosuppressive. Reduces flare frequency. Adverse Effect: Retinal toxicity and macular damage. Instruct patient to undergo comprehensive ophthalmology exams every $6\,\text{months}$.
  • Methotrexate: Non-biologic DMARD. Inhibits lymphocyte activity. Adverse Effects: Bone marrow suppression, hepatotoxicity, pulmonary fibrosis, teratogenicity.
  • Etanercept: Biologic TNF-inhibitor. Monitor for severe latent infection reactivation (TB); avoid live vaccines.
• Corticosteroids (e.g., prednisone): High-dose therapy for severe organ involvement or acute flares. Side effects: Hyperglycemia, osteoporosis, infection, hypertension, Cushingoid features.
• NSAIDs: For mild arthralgia and pleurisy.

Rheumatoid Arthritis

Pathophysiology

• Chronic, progressive, systemic autoimmune inflammatory disease primarily targeting the synovial joints.
• Autoantibodies (Rheumatoid Factor - RF, and anti-Cyclic Citrullinated Peptide - anti-CCP) attack synovial membranes.
• Synovial tissue undergoes hyperplastic thickening and converts into a destructive inflammatory vascular tissue (Pannus).
• Pannus invades and erodes articular cartilage, underlying bone, ligaments, and tendons, producing fibrous adhesions, calcifications, and complete joint bony ankylosis.

Clinical Manifestations

• Early Disease Findings: Symmetric joint inflammation/swelling (typically small joints of hands, wrists, feet), morning joint stiffness lasting $> 1\,\text{hour}$, joint pain, low-grade fever, fatigue, anorexia, paresthesias.
• Late Disease & Systemic Deformities:
  • Joint Deformities: Joint subluxation, Swan-Neck deformity, Boutonnière deformity, Ulnar drift/deviation.
  • Subcutaneous Rheumatoid Nodules: Firm non-tender nodules over extensor surfaces.
  • Vasculitis: Ischemic lesions around nail beds (periungual lesions).
  • Sjögren's Syndrome: Dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).
  • Felty's Syndrome: Rheumatoid arthritis combined with splenomegaly and severe neutropenia.
  • Pulmonary/Cardiac: Fibrotic lung disease, pericarditis.

Diagnostics & Management

• Diagnostic Tests: Positive Rheumatoid Factor (RF), positive anti-CCP antibodies (highly specific), elevated ESR and CRP, plain X-rays showing joint space narrowing and marginal erosions.
• Nursing Management:
  • Non-Pharmacological: Apply warm moist heat packs for morning joint stiffness; apply cold ice packs for acute edematous joint flares.
  • Critical Warning Sign: A single hot, swollen, intensely painful joint indicates acute Septic Arthritis and must be reported immediately.
  • Pharmacotherapy: Early aggressive treatment with Methotrexate, Hydroxychloroquine, Sulfasalazine, Biologic DMARDs (etanercept, infliximab), systemic Corticosteroids, and NSAIDs.

Atrial Fibrillation

Pathophysiology & Etiology

• Supraventricular tachydysrhythmia characterized by disorganized, uncoordinated, rapid electrical ectopy in the atria ($350-600\,\text{impulses/min}$).
• Results in total loss of atrial mechanical contraction ("atrial kick," which normally contributes $20\%-30\%$ of total cardiac output) and chaotic, irregular ventricular response ($120-200\,\text{bpm}$).
• Stasis of blood within non-contracting atria (especially the Left Atrial Appendage - LAA) creates a high risk of thrombus formation and systemic thromboembolism (ischemic stroke).
• Types: Paroxysmal ($< 7\,\text{days}$ duration; self-terminating), Persistent ($> 7\,\text{days}$), Long-Standing Persistent ($> 12\,\text{months}$), Permanent, Valvular (associated with mitral stenosis or artificial mechanical heart valve), Non-Valvular.
• Risk Factors: Hypertension, HF, CAD, valvular disease, hyperthyroidism, excessive alcohol ("Holiday Heart Syndrome"), sleep apnea, cardiac surgery.

Diagnostic Criteria

• 12-Lead Electrocardiogram (ECG):
  • Total absence of distinct P waves.
  • Presence of irregular, wavy fibrillatory baseline ($f$ waves).
  • Irregularly irregular ventricular response (RR intervals).

Pharmacotherapy Regimen

• Rate Control (Goal $HR < 110\,\text{bpm}$ resting):
  • Beta-Blockers (e.g., metoprolol, carvedilol).
  • Non-Dihydropyridine Calcium Channel Blockers (e.g., diltiazem, verapamil).
  • Digoxin (used in combined HF and A-Fib).
• Rhythm Control:
  • Antidysrhythmics: Amiodarone, dronedarone, flecainide, dofetilide, propafenone, ibutilide.
• Anticoagulation Therapy:
  • Valvular A-Fib: Requires Warfarin (Vitamin K antagonist; target INR $2.0-3.0$ or $2.5-3.5$ for mechanical valves).
  • Non-Valvular A-Fib: Direct Oral Anticoagulants (DOACs - apixaban, rivaroxaban, dabigatran). No routine lab monitoring required.
  • If A-Fib duration exceeds $48\,\text{hours}$, initiation of heparin or therapeutic anticoagulation is mandatory for a minimum of $3\,\text{weeks}$ prior to cardioversion (or perform TEE to rule out LAA thrombus) to prevent embolic stroke.

Interventions & Surgical Care

• Synchronized Electrical Cardioversion: Direct current synchronized to the R wave to reset SA node rhythm. Emergency resuscitation equipment must be present.
• Radiofrequency Catheter Ablation: Transvenous destruction of ectopic foci around pulmonary vein ostia.
• Left Atrial Appendage (LAA) Closure: Implantation of an occlusion device (e.g., Watchman) for non-valvular A-Fib patients with contraindications to long-term anticoagulants.
• Maze Surgical Procedure: Sutures/ablative lines placed in atrial myocardium to interrupt chaotic re-entry circuits.

Stroke (Cerebrovascular Accident)

Pathophysiology & Classifications

• Sudden loss of brain function resulting from disruption of cerebral blood supply.
• Cerebral tissue cannot store oxygen or glucose; $6\,\text{minutes}$ of complete ischemia produces irreversible brain death.
• Ischemic Stroke ($87\%$ of cases):
  • Thrombotic Stroke: Gradual occlusion of a cerebral or carotid artery by an atherosclerotic plaque clot. Slower onset.
  • Embolic Stroke: Sudden occlusion of a cerebral vessel by a dislodged embolus (typically originating from the heart secondary to Atrial Fibrillation, valvular disease, or acute MI). Rapid onset.
• Hemorrhagic Stroke:
  • Intracerebral Hemorrhage (ICH): Rupture of a vessel within brain parenchyma caused by severe chronic hypertension.
  • Subarachnoid Hemorrhage (SAH): Bleeding into the subarachnoid space caused by rupture of a saccular aneurysm or Arteriovenous Malformation (AVM). Manifests as a sudden, excruciating headache ("worst headache of my life"), nuchal rigidity, photophobia, projectile vomiting.

Lateralized Clinical Findings

• Left-Hemisphere Stroke: Right-sided hemiplegia/hemiparesis, right visual field deficits, aphasia (expressive - Broca's, receptive - Wernicke's, or global), agraphia, alexia, slow cautious behavior, awareness of deficits (causing depression and anxiety).
• Right-Hemisphere Stroke: Left-sided hemiplegia/hemiparesis, left visual field deficits, spatial-perceptual deficits, extreme impulsivity, poor judgment, short attention span, total lack of awareness of deficits (anosognosia / false confidence), unilateral neglect syndrome.

Assessment Metrics & Diagnostics

• National Institutes of Health Stroke Scale (NIHSS): Quantitative assessment scale ($0-42$; $0$ normal, $> 25$ severe stroke) measuring LOC, visual fields, facial palsy, motor arm/leg weakness, ataxia, sensory loss, speech/aphasia, dysarthria, and extinction/inattention.
• Non-Contrast Head CT Scan: Mandatory initial diagnostic test performed immediately upon arrival to differentiate ischemic from hemorrhagic stroke prior to initiating thrombolytic therapy.
• Carotid Duplex Ultrasound & MRI/MRA.

Emergency Interventions & Pharmacotherapy

• Fibrinolytic Therapy - Intravenous Alteplase (recombinant Tissue Plasminogen Activator - rtPA):
  • Dissolves fibrin clots to restore ischemic tissue perfusion.
  • Administration Criteria: Administer within $3\,\text{hours}$ (or up to $4.5\,\text{hours}$ in select patients) of last known normal time.
  • Contraindications: Active internal bleeding, blood pressure $> 185/110\,mmHg$, history of intracranial hemorrhage, recent major surgery or head trauma within $3\,\text{months}$, platelet count $< 100,000/mm^3$, INR > 1.7$.\n - Nursing Precautions: Maintain BP < 185/110\,mmHg$prior to infusion and$< 180/105\,mmHg$post-infusion using IV labetalol or nicardipine; perform neuro checks and vital signs every$15\,\text{minutes}$during infusion; do not insert invasive lines/catheters/NG tubes for$24\,\text{hours} post-infusion; monitor closely for sudden neuro decline or systemic bleeding.\n- Endovascular Thrombectomy (Mechanical Embolectomy): Intra-arterial clot retrieval catheter inserted via femoral artery for large vessel occlusions within 24\,\text{hours} of onset.\n- Management of Increased Intracranial Pressure (ICP):\n - Normal ICP is 5-15\,mmHg$; ICP$> 20\,mmHg requires treatment.\n - Interventions: Maintain HOB elevated at 30\,\text{degrees}$with head/neck in neutral alignment; avoid hip flexion; hyper-oxygenate before suctioning; prevent coughing or straining (administer stool softeners); maintain quiet environment; administer osmotic diuretics (Mannitol) or hypertonic ($3\%) saline as ordered.\n- Interprofessional Care: Keep patient strictly NPO until a formal dysphagia screening is completed by a Speech-Language Pathologist (SLP).\n- BE FAST Warning Signs: Balance loss, Eyesight changes, Facial drooping, Arm weakness, Speech difficulty, Time to call emergency services.\n\n---\n\n# Autism Spectrum Disorder\n\n## Pathophysiology & Etiology\n- Complex neurodevelopmental disability characterized by persistent deficits in social communication, social interaction, and restricted, repetitive patterns of behavior, interests, or activities.\n- Symptoms typically manifest during early childhood (ages 2-3\,\text{years}).\n- Etiology: Multifactorial genetic loci interactions combined with prenatal/environmental risk factors (advanced parental age, low birth weight, genetic conditions such as Fragile X syndrome, Down syndrome).\n\n## Clinical Manifestations\n- Social Communication & Interaction Deficits:\n - Avoidance of eye contact or inconsistent visual engagement.\n - Unresponsiveness to one's name or bids for social interaction.\n - Inability to engage in reciprocal conversation; echolalia (repeating words/phrases).\n - Monotone, sing-song, or robotic vocal pitch.\n - Difficulty understanding social cues, facial expressions, body language, or perspectives of others (theory of mind deficits).\n- Restricted & Repetitive Behaviors:\n - Repetitive motor movements (hand-flapping, body rocking, spinning).\n - Rigid adherence to specific routines; extreme distress over minor environmental alterations.\n - Highly fixated, intense interests (hyper-focus).\n - Sensory processing sensitivity: Hyper-reactivity or hypo-reactivity to sensory input (lights, sounds, clothing textures, temperatures).\n\n## Interventions & Therapy\n- Applied Behavior Analysis (ABA): Intensive behavioral modification therapy to enhance social skills, adaptive behaviors, and communication.\n- Speech Therapy, Occupational Therapy (sensory integration), Physical Therapy.\n- Pharmacotherapy: Atypical antipsychotics (risperidone, aripiprazole) FDA-approved to treat associated irritability, aggression, and self-injurious behavior.\n- Nursing Management: Maintain a calm, low-stimulation environment; maintain structured daily routines; explain all procedures thoroughly before touch; allow parents/caregivers to remain at bedside; utilize non-verbal communication boards.\n\n---\n\n# Attention-Deficit/Hyperactivity Disorder (ADD/ADHD)\n\n## Pathophysiology\n- Neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, impulsivity, or a combination, interfering with functional development.\n- Associated with dysregulation of central dopamine and norepinephrine neurotransmitter pathways in the prefrontal cortex.\n\n## Diagnostic Subtypes & Manifestations\n- Inattention Symptoms:\n - Making careless errors in schoolwork/tasks; lack of attention to details.\n - Difficulty sustaining focus during lectures or extended conversations.\n - Appearing not to listen when spoken to directly ("daydreaming").\n - Failure to complete tasks, assignments, or instructions.\n - Poor organizational skills, poor time management, missing deadlines.\n - Avoidance of tasks requiring sustained mental effort.\n - Losing essential objects (keys, eyeglasses, tools).\n - Easily distracted by extraneous stimuli; forgetfulness in daily activities.\n- Hyperactivity & Impulsivity Symptoms:\n - Fidgeting, squirming in seat, tapping hands/feet.\n - Inappropriately leaving seat in settings requiring sitting.\n - Running, climbing, pacing restlessly.\n - Inability to engage in quiet leisure activities.\n - Talking excessively; blurting out answers before questions are completed.\n - Difficulty awaiting one's turn; interrupting or intruding on others.\n\n## Pharmacotherapy Regimen\n- Central Nervous System Stimulants:\n - Methylphenidate (Ritalin) & Dextroamphetamine/Amphetamine (Adderall):\n - Mechanism: Blocks reuptake and increases synaptic release of dopamine and norepinephrine.\n - Adverse Effects: Insomnia, anorexia, weight loss, growth suppression, tachycardia, hypertension, dysrhythmias, anxiety, abuse potential.\n - Nursing Interventions: Administer in the morning immediately after breakfast to prevent anorexia and insomnia. Monitor height, weight, BP, and ECG baseline. Reduce caffeine intake.\n- Non-Stimulants:\n - Atomoxetine (Strattera):\n - Mechanism: Selective norepinephrine reuptake inhibitor.\n - Adverse Effects: Weight loss, liver toxicity, suicidal ideation in children/adolescents. Monitor LFTs.\n\n---\n\n# Psychosis & Psychotic Disorders\n\n## Spectrum Overview & Symptoms\n- Psychosis is a severe mental state characterized by a loss of contact with reality.\n- Spectrum Includes: Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Substance-Induced Psychotic Disorder.\n- Symptom Categories:\n - Positive Symptoms (Exaggeration of Normal Function):\n - Hallucinations: False sensory perceptions without external stimuli (Auditory - most common, Visual, Olfactory, Gustatory, Tactile, Command Hallucinations - dangerous voices ordering harm to self/others).\n - Delusions: Fixed false beliefs resistant to logical reasoning (Persecutory/Paranoid, Grandiose, Somatic, Reference, Jealousy, Control, Thought Insertion, Thought Withdrawal, Thought Broadcasting).\n - Alterations in Speech: Associative looseness, Neologisms (invented words), Echolalia, Clang associations (rhyming words), Word salad (jumbled incomprehensible speech), Tangentiality, Circumstantiality.\n - Bizarre Behavior: Catatonia, Waxy flexibility (holding rigid position for hours), Echopraxia (imitating movements), Echomimicry, Automatic obedience.\n - Negative Symptoms (Absence/Loss of Normal Function):\n - Affective flattening/blunting (diminished emotional expression).\n - Alogia (poverty of speech).\n - Avolition / Anergia (lack of motivation/energy).\n - Anhedonia (inability to feel pleasure).\n - Asociality (social withdrawal).\n - Cognitive Symptoms: Impaired abstract thinking, executive dysfunction, severe short-term memory deficits.\n\n## Antipsychotic Pharmacotherapy\n- First-Generation Antipsychotics (FGAs / Typical - e.g., haloperidol, chlorpromazine, loxapine):\n - Mechanism: Potent dopamine $D_2$ receptor antagonists.\n - Primary Indications: Treats positive psychotic symptoms.\n - Severe Adverse Effects:\n - Extrapyramidal Symptoms (EPS):\n - Acute Dystonia: Severe painful spasms of neck (torticollis), tongue, eyes (oculogyric crisis), or airway (laryngospasm). Treat immediately with IV/IM anticholinergics (benztropine or diphenhydramine).\n - Pseudoparkinsonism: Bradykinesia, mask-like face, shuffling gait, tremors.\n - Akathisia: Intense internal motor restlessness, pacing, inability to sit still.\n - Tardive Dyskinesia (TD): Involuntary, irreversible choreoathetoid movements of face, tongue (lip smacking, tongue protrusion), and limbs resulting from long-term therapy. Screen using Abnormal Involuntary Movement Scale (AIMS).\n - Neuroleptic Malignant Syndrome (NMS):\n - Life-threatening emergency. Characterized by sudden high fever (hyperpyrexia > 102^\circ\text{F}$/$38.9^\circ\text{C}), severe "lead-pipe" muscle rigidity, autonomic instability (fluctuating BP, tachycardia, diaphoresis), altered mental status, elevated creatine kinase (CK), and rhabdomyolysis.\n - Interventions: Immediately stop antipsychotic medication; administer IV dantrolene (muscle relaxant) or bromocriptine (dopamine agonist); initiate cooling blankets and IV hydration.\n- Second & Third-Generation Antipsychotics (SGAs / Atypical - e.g., risperidone, olanzapine, quetiapine, clozapine, aripiprazole):\n - Mechanism: Serotonin (5-\text{HT}{2A}$) and Dopamine ($D_2) receptor blockade.\n - Primary Indications: Treats both positive and negative symptoms; lower risk of EPS.\n - Adverse Effects: Metabolic Syndrome (severe weight gain, dyslipidemia, type 2 diabetes mellitus).\n - Clozapine Specific Warning: High risk of fatal Agranulocytosis. Requires mandatory weekly baseline ANC monitoring; withhold medication if Absolute Neutrophil Count (ANC) drops below 1000/mm^3\n\n## Nursing Interventions\n- Do not validate, reinforce, or argue with hallucinations or delusions. Validate the patient's feelings, but state reality clearly (e.g., "I do not hear the voices, but I understand they are frightening to you").\n- Intervene immediately for command hallucinations to prevent harm.\n\n---\n\n# Bipolar Disorder\n\n## Diagnostic Subtypes\n- Bipolar I Disorder: At least one full episode of Mania, alternating with Major Depressive episodes or Hypomania.\n- Bipolar II Disorder: Recurrent episodes of Major Depression alternating with at least one episode of Hypomania (never experienced full mania).\n- Cyclothymic Disorder: At least 2\,\text{years} of repeated hypomanic manifestations alternating with mild depressive symptoms.\n\n## Clinical Manifestations\n- Manic Episode Features:\n - Abnormally elevated, euphoric, expansive, or irritable mood.\n - Grandiosity, inflated self-esteem, inflated view of capabilities.\n - Decreased need for sleep (feeling rested after 2-3\,\text{hours}).\n - Pressured, rapid speech; Flight of ideas / racing thoughts.\n - Extreme distractibility, psychomotor agitation.\n - Excessive engagement in high-risk, impulsive activities (gambling, spending sprees, sexual indiscretions, reckless driving).\n - Neglect of personal hygiene, nutrition, and fluid intake.\n- Depressive Episode Features: Flat affect, psychomotor retardation, severe fatigue, anhedonia, tearfulness, suicidal ideation.\n\n## Pharmacotherapy Regimen\n- Mood Stabilizer - Lithium Carbonate:\n - Mechanism: Alters cation transport in nerve and muscle cells.\n - Therapeutic Window: 0.6 - 1.2\,mEq/L$for maintenance ($1.0 - 1.5\,mEq/L for acute mania).\n - Toxicity Thresholds & Symptoms:\n - Early Toxicity (1.5 - 2.0\,mEq/L): Coarse hand tremors, severe GI distress (persistent vomiting, diarrhea), slurred speech, lethargy, muscle weakness.\n - Advanced Toxicity (2.0 - 2.5\,mEq/L): Ataxia, giddiness, blurred vision, clonic movements, hyperreflexia, severe hypotension, large volumes of dilute urine.\n - Severe Toxicity (> 2.5\,mEq/L): Seizures, oliguria, renal failure, cardiac dysrhythmias, coma, death. Treat with Hemodialysis.\n - Nursing Interventions: Maintain baseline fluid intake (2-3\,L/day) and consistent dietary sodium intake. Decreased sodium intake or sodium depletion (diuretics, sweating, vomiting) causes kidneys to reabsorb lithium, resulting in severe toxicity. Monitor baseline renal function (BUN/creatinine) and thyroid function (lithium can induce goiter and hypothyroidism).\n- Antiepileptic Mood Stabilizers:\n - Carbamazepine & Valproic Acid / Valproate (Depakote - therapeutic blood level 50-125\,mcg/mL; risk of hepatotoxicity and pancreatitis).\n - Lamotrigine: High risk of Stevens-Johnson Syndrome (instruct patient to report any skin rash immediately).\n\n## Nursing Interventions During Acute Mania\n- Provide high-calorie, high-protein portable "finger foods" and fluids that can be consumed while walking.\n- Maintain a low-stimulation environment; enforce quiet rest periods.\n- Set firm, clear, non-judgmental limits on manipulative or high-risk behaviors.\n\n---\n\n# Ulcerative Colitis & Crohn's Disease\n\n## Pathophysiology & Etiology\n- Inflammatory Bowel Disease (IBD) comprised of two primary immune-mediated chronic intestinal conditions.\n- Ulcerative Colitis (UC):\n - Chronic inflammatory mucosal/submucosal condition confined exclusively to the colon and rectum.\n - Begins in the rectum and extends continuously upward through the colon in a uniform, linear fashion.\n - Mucosa becomes hyperemic, edematous, and ulcerated, forming micro-abscesses.\n- Crohn's Disease:\n - Chronic transmural (involving all bowel wall layers) inflammatory disease affecting any segment of the GI tract from mouth to anus (most commonly distal ileum and ascending colon).\n - Characterized by asymmetrical "skip lesions" (diseased segments interspersed between normal tissue) and a "cobblestone" mucosal appearance.\n - Transmural deep ulcerations produce deep fissures, strictures, deep abscesses, and complex fistulas (enterocutaneous, enteroenteric, enterovesical).\n\n## Comparative Manifestations\n- Ulcerative Colitis:\n - Severe bloody diarrhea with mucus (15-20\,\text{liquid stools/day}).\n - Left lower quadrant (LLQ) cramping abdominal pain.\n - Anorexia, weight loss, fever, anemia, hypoalbuminemia, fluid/electrolyte depletion (severe hypokalemia).\n - Complications: Severe rectal hemorrhage, Toxic Megacolon (massive colonic dilation > 6\,cm, fever, tachycardia, risk of perforation), and Colorectal Carcinoma.\n- Crohn's Disease:\n - Non-bloody diarrhea (5\,\text{loose stools/day}) containing mucus/pus.\n - Right lower quadrant (RLQ) abdominal pain/cramping.\n - Malabsorption, profound weight loss, severe malnutrition, steatorrhea, anemia, Vitamin B{12}$$ deficiency (megaloblastic anemia).
  • Complications: Intestinal strictures/obstruction, enterocutaneous or enterovesical fistulas, perianal abscesses.

Diagnostic Criteria

• Ulcerative Colitis: Sigmoidoscopy/Colonoscopy reveals continuous hyperemic, friable mucosal